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 Activation of the insulin receptor substrate (IRS)-1 is necessary for proper 
transduction of the insulin signal.  IRS-1 serine312(human)/307(rodent) phosphorylation, 
however, results in disruption of this signal and subsequent insulin resistance.  
Inflammatory mediators, such as the inhibitor of κB kinase β (IKKβ), interrupt 
insulin signaling within insulin-sensitive tissues, such as skeletal muscle.  In 
contrast, AMP-activated protein kinase (AMPK), a key metabolic enzyme, 
increases insulin sensitivity.  To study the association of IKKβ and AMPK, muscle 
biopsies were taken from post-bypass patients and control subjects.  Post-
bypass patients displayed similar levels of IKKβ action and IRS1-pSer312 as the 
lean subjects and reduced levels compared with weight-matched control and 
morbidly obese subjects, which supports evidence that IKKβ phosphorylates IRS-
1 Ser312 and reduces the insulin signal, resulting in reduced whole-body insulin 
sensitivity.  However, these findings did not correlate with baseline differences in 
AMPK phosphorylation. 
 To explore the role of AMPK in attenuating IKKβ activity and ameliorating 
insulin resistance, lean and obese Zucker rats were treated with metformin, an 
AMPK activator.  Despite no differences at baseline, AMPK action was increased 
with metformin treatment in a fiber-type specific (white muscle) manner with a 
reduction in IKKβ activity and IRS1-pSer307 in the muscle of obese rats only.   
  
To explore this relationship further, myotubes from lean and morbidly 
obese humans were exposed to the saturated fatty acid palmitate in the 
presence or absence of AICAR to activate AMPK.  In contrast to the lean, obese 
myotubes demonstrated no depression in insulin signaling with lipid exposure.  
Co-incubation with AICAR prevented the lipid-induced decay of the insulin signal 
in the lean and improved the signal in the obese.  AICAR-stimulated AMPK 
activation for the final 4 h of lipid exposure was not sufficient to restore 
phosphorylation of AS160.   
These data support the hypothesis that lipids induce insulin resistance via 
lipid-sensitive serine kinases that attenuate insulin signaling.  Whereas AMPK 
activity does not appear to play a role in baseline differences of IKKβ action and 
insulin signaling, we present findings that the lipid-induced decay in the insulin 
signal can be prevented by acute activation of AMPK.  These results provide 
valuable information explaining differences in skeletal muscle function in the lean 
and obese, as well as elucidating a potential mechanism for insulin-sensitizing, 
AMPK-activating agents.   
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As a result of our modern western lifestyle, people are suffering from 
unique infirmities rarely seen in previous generations.  Among these is obesity—
the second leading cause of preventable death in the country and a problem that 
is becoming increasingly prevalent in our society.  Over 66% of adults in the U.S. 
are considered overweight or obese, with 4.8% being extremely obese—a 
category that did not exist previously.  Additionally, among children and 
adolescents, over 17% are considered overweight with over 33% ‘at risk’ (Ogden 
et al., 2006).  Moreover, an overweight child has a 70% chance of being an 
overweight or obese adult (The Surgeon General's Call To Action To Prevent and 
Decrease Overweight and Obesity, 2007).  Once thought to be a malady unique 
to western, wealthy societies, obesity is now a concern in less affluent countries 
as well (Popkin, 1998; Vainio, Kaaks, & Bianchini, 2002). 
Obesity results in a host of health complications, including cardiovascular 
disease (CVD) (Sjostrom, Lissner, Wedel, & Sjostrom, 1999), which accounts for 
more deaths in the U.S. than any other disease, hypertension (Wilson, 
D'Agostino, Sullivan, Parise, & Kannel, 2002), osteoarthritis (Hart & Spector, 
1993), and type 2 diabetes mellitus (Flegal, Graubard, Williamson, & Gail, 2007).  
More specifically, being obese increases the risk of developing diabetes to a 
relative risk of 40 and 60.9 compared to lean individuals in women and men, 
respectively (Chan, Rimm, Colditz, Stampfer, & Willett, 1994; Colditz, Willett, 
Rotnitzky, & Manson, 1995; Malnick & Knobler, 2006).  Moreover, approximately 
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half of obese and overweight people have significant insulin resistance, a 
hallmark of type 2 diabetes mellitus (McLaughlin et al., 2001).   
Research within the last decade has revealed that one possible link 
between obesity and insulin resistance is the NF-κB pathway and its associated 
inflammatory cytokines that stems from the chronic and excessive lipid circulation 
and accumulation in non-adipose tissue sites, which is a prominent feature of 
obesity (Wellen & Hotamisligil, 2005).  In contrast to the insulin-resistant effects 
of excessive lipid, AMP-activated protein kinase (AMPK), a key metabolic 
enzyme, acts to improve insulin sensitivity, potentially counter-acting the 
deleterious effects of lipid excess.  Inasmuch as skeletal muscle is the main 
consumer of glucose in vivo, studying the effects of lipid-induced inflammatory 
cytokines on insulin-mediated glucose uptake in skeletal muscle, and the role of 
AMPK in possibly mitigating this response, holds great potential for addressing 
the obesity-diabetes relationship. 
Insulin Signaling Pathway 
 The process through which insulin binds to a receptor and ultimately leads 
to the uptake of glucose into the cell has been the focus the extensive research 
for decades, yet despite this research, the precise pathway is not fully 
understood.  Glucose diffuses across the plasma membrane very slowly and 
inasmuch as glucose is the primary fuel for most cells of the body, it is imperative 
that the cell have a way whereby it can rapidly allow glucose to enter the cell.  As 
such, many cell types in the body, including myocytes, red blood cells, 
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adipocytes, and hepatocytes, possess glucose transporters, with glucose 
transporter-4 (GLUT4) being the key insulin-responsive transporter.  Whereas 
the intermediates in the insulin signaling pathway are not fully understood, the 
primary step, the binding of insulin to its receptor, and the final step, the 
translocation of GLUT4 from intracellular vesicles to the plasma membrane, are 
well characterized (Bryant, Govers, & James, 2002).    
The insulin signal pathway begins with the insulin receptor, which is a 
transmembrane heterotetrameric glycoprotein.  Two of the receptor’s subunits 
protrude into extracellular space with two intracellular subunits that contain 
tyrosine residues (Ullrich et al., 1985).  The insulin receptor is capable of 
autophosphorylation at these tyrosine residues and they subsequently 
phosphorylate the insulin receptor substrate (IRS)-1, among others, which is a 
pivotal step in the transduction of the activation of the insulin signal.  Upon 
activation, phosphorylated IRS-1 recruits a number of effectors, including 
phophoinositol 3-kinase (PI3K), which is a heterodimer of a catalytic (p110) and 
regulatory (p85) subunit.  The p85 subunit interacts with IRS-1, leading to 
increased PI3K activity, and PI3K, in turn, causes the production of 
phosphatidylinositol-3,4,5-triphosphate (PIP3).  PIP3 recruits Akt to the plasma 
membrane by supplying docking sites that place Akt in close proximity to its 
upstream activator, phosphatidylinositol-dependent kinase-1 (PDK-1)(Bryant et 
al., 2002).  Until very recently, the activation of Akt was thought to be the 
concluding step prior to GLUT4 translocation.  However, a substrate of Akt has 
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been identified that offers a link between Akt and GLUT4 mobilization.  This link, 
an Akt substrate of 160 kDa (AS160), is a GAP protein—a family of GTPases 
that regulate numerous membrane trafficking processes (Deneka, Neeft, & van 
der Sluijs, 2003).  The proposed role for AS160 in regards to GLUT4 is that 
phosphorylation of AS160 inhibits its GAP activity; consequently, the GTP form of 
a Rab(s) required for GLUT4 translocation is elevated, and thus translocation is 
triggered (Miinea et al., 2005; Sano et al., 2003).  Finally, upon reaching the 
plasma membrane, GLUT4 proteins form an aqueous pore across the membrane 
through which glucose can move.   
Insulin Receptor Substrate (IRS)-1 Dysfunction 
 Due to its location at the proximal end of the pathway, any dysfunction in 
the action of IRS-1 can result in disruption of the entire cascade.  Hence, this 
area has received a great deal of attention in recent years.  Yamauchi et al. 
(Yamauchi et al., 1996) observed that skeletal muscle from IRS1-deficient 
rodents exhibited reduced insulin-stimulated glucose uptake.  Further, it has 
been shown using short interfering (si) RNA-mediated ablation of IRS-1 that the 
loss of IRS-1 function results in reduced insulin-stimulated glucose uptake, Akt 
phosphorylation, and GLUT4 translocation (Huang, Thirone, Huang, & Klip, 
2005).   
A unique characteristic of IRS-1 is the presence of multiple tyrosine 
phosphorylation sites (Thirone, Huang, & Klip, 2006).  Whereas tyrosine 
phosphorylation of insulin-receptor substrate (IRS)-1 by the insulin receptor is 
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necessary for normal signaling, the phosphorylation of other sites may disrupt 
normal function.  In particular, serine phosphorylation of IRS-1 has been 
implicated in inhibiting insulin signal transduction (Cai et al., 2005; Yuan et al., 
2001) and the IRS-1 Ser312 (Human)/307(rodent) residue has received particular interest 
given its proximity to the phosphotyrosine-binding (PTB) domain in IRS-1.  IRS-1 
undergoes a conformational change as a result of serine phosphorylation that 
decreases its ability to interact with the insulin receptor, making it a poor 
substrate for the insulin receptor (Aguirre et al., 2002). 
Inflammatory Mediators Inhibit Insulin Signaling 
An interesting area of research has developed in recent years, which 
explores the role of inflammatory mediators in metabolic functions.  Whereas the 
immune and metabolic systems were once thoughts of as distinct, they appear to 
work jointly in maintaining healthy function.  However, such a realization should 
come as no surprise given that these systems represent the most indispensable 
abilities within an organism—the ability to defend itself against infection and heal 
and the ability to store energy for times of low nutrient availability and high 
energy demand.  For example, several hormones and cytokines not only mediate 
both metabolic and immune processes, but also operate through similar cellular 
mechanisms.  As such, these systems are interdependent and work 
synergistically to maintain homeostasis.   
The first molecular link between inflammation and metabolic function was 
the discovery that tumor necrosis factor α (TNFα) is overexpressed in adipocytes 
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of rodent models of obesity approximately 15 years ago (Hotamisligil, Shargill, & 
Spiegelman, 1993).  Subsequent research has revealed similar results in human 
adipose tissue (Festa et al., 2001), as well as in rodent and human skeletal 
muscle (Borst & Conover, 2005; de Alvaro, Teruel, Hernandez, & Lorenzo, 2004; 
Jove et al., 2006).  However, it has become clear that the presence and 
overexpression of TNFα is among a host of results that stem from the activities of 
a key player in the inflammatory, immune response, specifically the nuclear 
factor κB (NF-κB).   
NF-κB has garnished a great deal of attention in recent years due to its 
newfound role in regulating metabolic activities.  NF-κB was first discovered over 
20 years ago and was thought to be unique to B cells (Sen & Baltimore, 1986), 
though now it is known to be ubiquitous.  Within the cell NF-κB is retained in the 
cytoplasm in an inactive form bound to specific inhibitors, the IκB proteins.  When 
bound in the cytosol by its inhibitors NF-κB is in an inactive form, however, upon 
degradation of IκB, which is an essential step in this process, NF-κB translocates 
to the nucleus and elicits transcription of a host of cytokines and other 
inflammatory mediators.  The signal is eventually terminated through the export 
and cytoplasmic resequestration of NF-κB, which is contingent on the newly 
synthesized IκBα isoform entering the nucleus, binding NF-κB and causing its 
dissociation from the DNA strand (Arenzana-Seisdedos et al., 1997).  Because 
IκBα, the best characterized isoform, is so critical to the NF-κB pathway, the 
study of its regulation revealed an upstream kinase named the inhibitor of IκB 
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kinase (IKK) (J. A. DiDonato, Hayakawa, Rothwarf, Zandi, & Karin, 1997).  In 
fact, IKK is considered to be the key to activating the canonical NF-κB pathway 
(Karin & Ben-Neriah, 2000).   
Of IKK’s three subunits (α, β, γ), the function of the catalytic β subunit is 
the most thoroughly elucidated due to its interaction with and phosphorylation of 
IκBα (Klement et al., 1996).  For IKKβ to induce the degradation of IκBα, IκBα 
must be phosphorylated at two serine residues, 32 and 36, which results in its 
polyubiquitinylation and subsequent degradation by the 26S proteosome (J. 
DiDonato et al., 1996; J. A. DiDonato, Mercurio, & Karin, 1995).  Indeed, the 
presence or absence of IκBα is so reflective of IKKβ activity, and is so vital in this 
process, that it is frequently measured as indicator of IKKβ and NF-κB pathway 
activity (Bikman et al., 2008; Coll et al., 2006; Jove, Planavila, Laguna, & 
Vazquez-Carrera, 2005; Jove et al., 2006; Schenk & Horowitz, 2007).     
Interestingly, IKKβ exacerbates insulin resistance through two known 
pathways.  First, through activation of NF-κB, which stimulates the synthesis of 
multiple cytokines and activation of multiple kinases that disrupt insulin signal 
transduction (Bastard et al., 2006; Ropelle et al., 2006).  Second, IKKβ is a 
serine kinase that has been implicated in causing deficient insulin signal 
transduction through its phosphorylation of IRS-1 Ser312/307 (Arkan et al., 2005; 
Cai et al., 2005; McLaughlin et al., 2001; Yuan et al., 2001).   
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Excess Lipid Activates IKKβ and Inhibits Insulin Signaling 
In addition to having multiple pathways of action, IKKβ itself is activated by 
multiple upstream events (Figure 1.1).  Unsurprisingly, cytokines trigger IKKβ, 
but, interestingly, IKKβ is also activated by lipid accumulation and lipid 
metabolites, such as diacylglycoerol (DAG) (Itani, Ruderman, Schmieder, & 
Boden, 2002; Lee et al., 2006; C. Yu et al., 2002), and ceramide (Chavez et al., 
2003; Schmitz-Peiffer, 2002; C. Yu et al., 2002), which have all been shown to be 
higher in insulin resistant states, such as obesity (Itani et al., 2002).  While a 
tremendous amount of research has revealed an association between 
intramuscular triglyceride accumulation and insulin resistance, triglycerides are 
more and more perceived as the metabolically inert (Schenk & Horowitz, 2007) 
acquaintances of the more favored suspects just mentioned (DAG, ceramide).  
Evidence also supports the role of the activated form intracellular fatty acid—
long-chain acyl-coenzyme A (LCACoA)(Nakamura & Nishizuka, 1994). 
Recent work has effectively established the role of inflammatory cytokines 
in lipid-induced insulin resistance by preventing the inflammatory response.  For 
example, Ikkβ+/- mice have lower fasting glucose and insulin concentrations 
compared to Ikkβ+/+ littermates when on high-fat diets, demonstrating that a 
reduction in the Ikkβ gene may protect against insulin resistance (Yuan et al., 
2001).  Additionally, IKKβ KO mice experience no decrement in insulin sensitivity 
in response to lipid infusion compared to control mice (Kim et al., 2001).  Finally, 
  
10
lipid infusion in humans resulted in significantly reduced levels of IκB, the NF-κB 
inhibitor that is degraded by IKKβ, during a 6-hr time course (Itani et al., 2002). 
The excess lipid that results from the obese state may explain the 
observation that obesity is associated with an increased low-grade inflammatory 
tone, as evidenced by increased levels of proinflammatory cytokines and NF-κB 
activity (Bastard et al., 2006; Festa et al., 2001; Permana, Menge, & Reaven, 
2006; Warnberg & Marcos, 2008).  Our group has previously shown that obesity 
is associated with reduced insulin-stimulated glucose uptake (Dohm et al., 1988) 
and that weight loss, through both lifestyle intervention (Houmard et al., 2004) 
and surgery (Bikman et al., 2008; Gray, Tanner, Pories, MacDonald, & Houmard, 
2003; Houmard et al., 2002), reduces intramuscular lipid and improves insulin 
sensitivity in humans.  Moreover, inflammation is reduced with weight loss 
(Bastard et al., 2006).   
AMPK Activation Improves Insulin Sensitivity through Improved Signaling 
and Reduced Inflammatory Activity 
Whereas inflammatory cytokines and NF-κB pathway intermediates inhibit 
insulin signaling, AMPK plays a key role in increasing insulin sensitivity.  In fact, a 
deficiency in AMPK activity has been implicated in the onset of type 2 diabetes 
(Winder & Hardie, 1999).  In skeletal muscle, AMPK directs lipid and glucose 
metabolism in an effort to restore cellular levels of ATP, regulating energy 
balance within the cell (Carling, 2004; Hardie, 2004).  As such, AMPK is potently 
activated by reduced ATP levels within the cell.  AMPK can also be covalently 
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activated by upstream kinases.  AMPK’s role in the cell is evidently so vital to 
proper metabolic function that it is highly conserved in all eukaryotic species and 
ubiquitous in mammalian cells (Hardie, Scott, Pan, & Hudson, 2003).   
Regardless of the stimulus, upon activation AMPK phosphorylates several 
downstream substrates with the general trend of upregulating ATP-generating 
pathways and inhibiting ATP-consuming pathways with the end result being a 
restoration of the AMP/ATP ratio (Winder, 2001).  A host of insulin-sensitizing 
drugs have been shown to act, in part, through inhibition of NF-κB pathway 
activity, including salicylate (McLaughlin et al., 2001), thiazolidinediones 
(TZDs)(Ghanim et al., 2001; LeBrasseur et al., 2006; Todd, Watt, Le, Hevener, & 
Turcotte, 2007), and metformin (Cleasby et al., 2004; G. Zhou et al., 2001).  
Interestingly, evidence indicates that both TZDs and metformin increase activity 
of AMPK (LeBrasseur et al., 2006; Lessard et al., 2006; Ye et al., 2006).  Two of 
the primary consequences of AMPK activation are an increase in glucose uptake 
by AMPK-driven phosphorylation of AS160 (Thong, Bilan, & Klip, 2007), which 
facilitates the insulin signal, and stimulating mitochondrial import and oxidation of 
fatty acids by disinhibiting carnitine palmitoyl transferase-1 (Ferre, Azzout-
Marniche, & Foufelle, 2003; McGarry, 2002).  Through this process AMPK likely 
prevents the accumulation of lipid metabolites that activate NF-κB pathway 
intermediates and disrupts insulin signal transduction (Fediuc, Pimenta, Gaidhu, 
& Ceddia, 2008).  However, AMPK has also been shown to prevent cytokine-
induced NF-κB pathway stimulation and result in reduced IKKβ action (Cacicedo, 
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Yagihashi, Keaney, Ruderman, & Ido, 2004; Cleasby et al., 2004; Hattori, Suzuki, 
Hattori, & Kasai, 2006; Hattori et al., 2008), suggesting a more direct effect of 
AMPK on the NF-κB pathway.   
AMPK and Inflammatory Intermediates in Endothelial Cells and Liver 
The initial research investigating the novel role of AMPK as a mediator in 
inflammation was conducted with endothelial cells.  This research began in 
endothelial cells likely due to the interest in inflammation-induced 
atherosclerosis.  As a result, it was determined that AMPK inhibits both fatty acid- 
and TNFα-induced increases in NF-κB in cultured endothelial cells (Cacicedo et 
al., 2004).  When endothelial cell cultures were incubated with palmitate, 
inflammatory markers, i.e. VCAM-1, increased, but this response was attenuated 
in the presence of AICAR.  Moreover, AICAR acted to prevent NF-κB activation 
in the presence of TNFα.  This provides strong evidence in support of AMPK’s 
role in attenuating inflammation.  Additionally, metformin, an AMPK-activating 
drug, dose-dependently inhibited TNFα-induced NF-κB activation.  Further, small 
interfering RNA for AMPKα1 attenuated metformin- and AICAR-induced inhibition 
of NF-κB activation by TNFα, further supporting a role for AMPK (Hattori et al., 
2006).  In a study with macrophages, cells were pretreated with AICAR for one 
hour followed by LPS infusion.  The LPS insult failed to increase TNFα when 
preceded by AICAR incubation (Jhun et al., 2004). 
Additionally, research involving metformin has displayed anti-IKKβ 
properties in the liver.  Cleasby et al. (Cleasby et al., 2004) observed elevated 
  
13
levels of IκBα in liver from metformin-treated rodents, providing indirect evidence 
that AMPK may be serving as an IKKβ inhibitor in an insulin sensitive tissues.  
These findings provide the rationale for exploring the potential role of AMPK as 
an IKKβ inhibitor in skeletal muscle inasmuch as muscle represents the main site 
of insulin-dependent glucose uptake. 
AMPK and Inflammatory Intermediates in Skeletal Muscle 
In skeletal muscle from sedentary rats, AICAR (an AMPK activator) and 
insulin co-incubation was shown to induce a twofold greater glucose uptake 
compared to insulin alone (Fisher, Gao, Han, Holloszy, & Nolte, 2002).  
Moreover, muscle contraction was shown to increase AMPK activity similar to 
that induced by AICAR, shedding light on potential mechanisms of contraction-
mediated glucose uptake.  Similarly, AICAR-perfused rat hindlimbs have been 
shown to increase glucose uptake compared with controls (Merrill, Kurth, Hardie, 
& Winder, 1997).  In addition, reductions in AMPK activity are associated with 
diet-induced insulin resistance (Bonnard, Durand, Vidal, & Rieusset, 2008) and 
ablation of AMPK in skeletal muscle was observed to exacerbate lipid-induced 
insulin resistance (Fujii et al., 2008).   
The idea of AMPK attenuating inflammatory activity in skeletal muscle has 
only recently been investigated and, due to a lack of research, a consensus has 
yet to be reached.  For example, Steinberg et al. (Steinberg et al., 2006) 
observed that muscle cells with constitutively active AMPK were protected from 
TNFα-induced suppression of insulin-stimulated glucose uptake (TNFα has been 
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shown to elicit an increase in IKKβ activity).  In ob/ob mice they found that AMPK 
activity was significantly reduced compared with lean controls and that TNFα 
neutralization in ob/ob mice restored AMPK activity to that of lean controls.  
Furthermore, obese mice exhibited reduced fatty acid oxidation, a defect that 
was not observed following TNFα neutralization.  Lastly, ob/ob mice lacking a 
functional TNFα receptor (TNF -/-) enjoy greater insulin sensitivity than control 
ob/ob mice.  It was observed that AMPK activity was higher in obese TNF -/- 
relative to obese controls.  Whereas the evidence provided by Steinberg et al. 
(Steinberg et al., 2006) places inflammatory mediators upstream of AMPK, the 
work by Hattori et al. (Hattori et al., 2006) in endothelial cells offer the opposite 
perspective—that AMPK inhibits NF-κB pathway activity.  Interestingly, AICAR 
treatment  in human myotubes has also been found to decrease cytokine 
production (Lihn, Pedersen, Lund, & Richelsen, 2008). 
The role of AMPK in the etiology of insulin resistance has more recently 
been explored by observing the effects of HFD in mice expressing a muscle-
specific transgenic ablation of AMPKα2 (Fujii et al., 2008).  In addition to having a 
50% reduction in insulin-stimulated glucose transport compared with wild type 
mice, muscle from the transgenic (TG) mice had reduction in insulin receptor β, 
IRS-1, and Akt.  Moreover, whereas muscle DAG concentrations were not 
different between wild type and TG mice on the control diet, HFD caused an 
elevation in DAG levels in the TG mice only.  Though not measured, it is 
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tempting to conclude that HFD TG mice might suffer from elevated IKKβ activity 
and inhibited insulin signaling.   
AMPK Activity is Unclear in Obesity 
Interestingly, recent studies suggest that there may be defective AMPK 
action in the presence of excessive lipid accumulation in obese subjects.  This 
discovery may represent a mechanism by which lipid-induced insulin resistance 
and inflammation occur (Bruce, 2005; Chen, Liu, Sun, Tang, & Deng, 2005).   
Despite obesity being causally linked with inflammation, the sparse 
amount of data linking obesity with reduced levels or activity of AMPK in humans 
are conflicting.  Steinberg et al. (2004) and Bruce et al. (2005) observed no 
difference between lean and obese levels of skeletal muscle AMPK subunit 
mRNA as well as basal AMPK activity (and p-ACC).  In contrast, the study by 
Bandyopadhyay et al. (2006) revealed very different results.  In this study, obese 
subjects had far less total basal p-AMPK level and activity compared to lean 
subjects.  Lastly, p-ACC was also dramatically reduced in obese compared to 
lean.  It is clear that more research is warranted.   
In contrast to humans, research investigating the same relationship in 
rodents is far more conclusive, establishing a clear reduction in AMPK activity 
with obesity (Barnes et al., 2002; Sriwijitkamol et al., 2006; Ye et al., 2006; X. Yu 
et al., 2004).  In particular, obese insulin-resistant Zucker rats have reduced 
AMPK activity and related signaling abnormalities in skeletal muscle (Barnes et 
al., 2002; Bergeron et al., 2001). 
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In addition to elucidating the relationship between obesity and AMPK 
activity, it is worthwhile to explore the effects of high-fat feeding on AMPK 
activity.  In one study, high-fat fed rodents experienced a significant decline in 
both level and activity of AMPK (Liu, Wan, Guan, Gao, & Zhao, 2006).  In vitro 
studies have demonstrated that LCACoAs inhibit AMPK activity (Taylor, 
Ellingson, Lamb, Chesser, & Winder, 2005).  Moreover, high-fat–fed rats have 
accumulated tissue LCACoAs, further suggesting an inverse relationship 
between high-fat diet and AMPK activity (Ye et al., 2003).  However, in a 
separate study AMPK levels were not significantly different between high-fat- and 
chow-fed rats (Martin et al., 2006).  Despite the lack of research exploring the 
relationship between high-fat feeding and AMPK activity in humans, the 
relationship between high-fat-diet induced elevations in inflammation is well 
established (Borst & Conover, 2005; Morin, Eckel, Marcel, & Pagliassotti, 1997). 
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Statement of the Problem   
AMPK’s role in healthy metabolic function is vital and the question of 
whether AMPK affects the IKKβ response to lipid accumulation in muscle is 
essential to understanding lipid-induced insulin resistance.  Due to the 
prevalence of obesity in our society and the fact that obesity is associated with 
elevated free fatty acids and increased incidence of type 2 diabetes mellitus, one 
method to elucidate the role of AMPK in improving lipid-induced insulin 
resistance via attenuation of the inflammatory pathway is to observe this 
relationship in obese, lean, and weight-loss subjects.  If AMPK activity is altered 
between obese, lean, and weight-loss subjects, it may offer some explanation 
concerning the deleterious consequences of obesity.  Moreover, considering that 
metformin is such a widely prescribed anti-diabetic drug and AMPK activator 
despite its precise mechanisms remaining elusive, it seems worthwhile to explore 
its role in conditions that mimic the lifestyles of the majority of those who suffer 
from diabetes, diet-induced obesity.  Further, recent and convincing data from 
endothelial cells and liver have uncovered a significant effect of AMPK to inhibit 
the lipid-induced increase in inflammatory cytokine activity.  However, AMPK’s 
ability to counter the deleterious consequences of elevated lipids has not been 
explored in muscle, which represents a truly meaningful area of research 
considering skeletal muscle’s vital role in healthy insulin responsiveness.  Hence, 
we feel it is crucial to determine the effect of AMPK manipulation in skeletal 
muscle in attenuating lipid-induced insulin resistance via inhibition of IKKβ. 
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Figure 1.1.  Proposed pathway through which AMPK potentially inhibits IKKβ 
activity and improves insulin signaling in skeletal muscle. 
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Abstract 
Surgical treatments of obesity have been shown to induce rapid and 
prolonged improvements in insulin sensitivity.  To investigate the effects of 
gastric bypass surgery and the mechanisms that explain the improvement in 
insulin sensitivity we employed a cross-sectional, non-randomized, controlled 
study.  This study was conducted jointly between the Departments of Exercise 
Science and Physiology at East Carolina University in Greenville, NC.  Subjects 
were recruited into four groups: 1) lean (BMI<25; n=93), 2) weight-matched 
(BMI=25 to 35; n=310), 3) morbidly obese (BMI>35; n=43), and 4) post-surgery 
patients (BMI≈30 kg/m2; n=40).  Post-surgery patients were weight stable one 
year post surgery.  Whole-body insulin sensitivity, muscle glucose transport, and 
muscle insulin signaling were assessed as markers of glucose uptake and insulin 
sensitivity.  Post-surgery subjects had insulin sensitivity index values that were 
similar to the lean and higher than morbidly obese and weight-matched control 
subjects.  Glucose transport was higher in the post-surgery vs. morbidly obese 
and weight-matched groups.  IRS1-pSer312 in the post-surgery group was lower 
than morbidly obese and weight-matched groups.  IκBα was higher in skeletal 
muscle from the post-surgery patients when compared to the morbidly obese and 
weight-matched controls, indicating reduced IKKβ activity.  Insulin sensitivity and 
glucose transport were greater in the post-surgery patients than predicted from 
the weight-matched group, suggesting improved insulin sensitivity after bypass is 
due to something other than, or in addition to, weight loss.  We conclude that 
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improved insulin sensitivity following gastric bypass surgery is related to reduced 
IKKβ activity and enhanced insulin signaling in muscle.   
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Introduction 
Gastric bypass surgery has been employed as a tool to assist in weight 
loss in morbidly obese individuals.  For over 20 years, our group has been 
performing gastric bypass surgery, which consists of surgical reduction in the 
size of the stomach and bypassing a portion of the proximal small intestine.  We 
were the first to report that gastric bypass surgery results in rapid and long term 
improvement in insulin sensitivity and an ultimate reversal of diabetes (Friedman 
et al., 1992; Pories, 1992; Pories et al., 1992).  More recently, Dixon et al (Dixon 
et al., 2008) observed that laparoscopic adjustable gastric banding (LAGB) 
resulted in a higher remission rate of type 2 diabetes compared with conventional 
medical treatment.  Additionally, the reversal of diabetes by various surgical 
treatments of obesity was confirmed by meta-analysis, wherein gastric bypass 
surgery and LAGB were found to resolve diabetes in approximately 84% and 
48% of post-surgery patients, respectively (Buchwald et al., 2004). 
Although an increase in whole-body insulin sensitivity after gastric bypass 
surgery is well established, the mechanisms involved are not fully understood.  A 
potential signaling defect in the insulin signaling cascade in the muscle of obese 
and type 2 diabetics may be a cause for reduced insulin sensitivity.  We have 
shown previously that insulin-stimulated muscle glucose transport is blunted in 
obese individuals and patients with type 2 diabetes and that insulin-receptor 
tyrosine kinase activity is diminished in obese and diabetic skeletal muscle 
(Dohm et al., 1988; Q. Zhou, Dolan, & Dohm, 1999).  Serine phosphorylation of 
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the insulin receptor substrate (IRS)-1 has been implicated in inhibiting insulin 
signal transduction (Cai et al., 2005; Yuan et al., 2001) and while there are many 
potential serine phosphorylation sites on IRS-1 (Morino, Petersen, & Shulman, 
2006), the IRS1 Ser312 (Human)/Ser307(rodent) residue is of particular interest given its 
proximity to the phosphotyrosine-binding (PTB) domain in IRS-1.  The inhibitor of 
κB kinaseβ (IKKβ), a serine kinase, has been suggested as a potential culprit 
that results in deficient insulin signal transduction given that it has been shown to 
phosphorylate IRS-1 on Ser312/307 (Arkan et al., 2005; Cai et al., 2005; Kim et al., 
2001; Yuan et al., 2001).  Moreover, IKKβ is activated by fatty acid metabolites, 
such as diacylglycoerol (DAG) and ceramide (Schmitz-Peiffer, 2002; C. Yu et al., 
2002), which have been shown to be higher in insulin resistant states, such as 
obesity (Itani et al., 2002).   
Obesity is associated with an increased low-grade inflammatory tone, as 
evidenced by increased levels of proinflammatory cytokines as well as greater 
activity of the inflammatory factor, NF-κB (Bastard et al., 2006; Festa et al., 2001; 
Permana et al., 2006; Warnberg & Marcos, 2008).  NF-κB is a nuclear 
transcription factor that is responsible for the transcription of a multitude of 
cytokines (including TNF-α and IL-1β) (Granger, Vowinkel, & Petnehazy, 2004; 
Piva, Belardo, & Santoro, 2006).  NF-κB is prevented from reaching the nucleus 
by an inhibitor, known as inhibitor κBα (IκBα).  IκBα is phosphorylated by IKKβ, 
which results in the ubiquitination and degradation of IκBα and NF-κB is free to 
migrate into the nucleus.  In addition to regulating NF-κB activity, IKKβ has been 
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shown to directly inhibit insulin signaling (Cai et al., 2005; Ghanim et al., 2001; 
Yuan et al., 2001).  To highlight the role of NF-κB pathway activity in inhibiting 
insulin signaling, thiazolidinediones, a known insulin-sensitizing drug, inhibit NF-
κB activity (Ghanim et al., 2001; Todd et al., 2007).  Similarly, Yin et al. (Yin, 
Yamamoto, & Gaynor, 1998) discovered that the mechanism of action for 
salicylate in improving insulin sensitivity was its inhibitory actions on IKKβ.   
       We are interested in the causes of insulin resistance in muscle of obese 
individuals and the mechanisms that improve insulin resistance after patients 
have gastric bypass surgery.  The purpose of this study was to investigate gastric 
bypass surgery-induced increases in insulin sensitivity at the whole body and 
muscle level.  We also sought to determine a potential mechanism for the rapid 
and sustained improvement in insulin sensitivity as a result of gastric bypass 
surgery.   
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Materials and Methods 
Subjects and study design   
To investigate the reversal of insulin resistance after bypass surgery three 
experiments were performed.  In the first experiment whole-body insulin 
sensitivity was measured in post-surgery patients and non-surgical controls by an 
intravenous glucose tolerance test (IVGTT) as outlined below.  The second 
experiment involved glucose transport measured in rectus abdominis muscle 
strips from patients having elective surgery.  These values were compared to 
previous data published for gastric bypass patients after weight loss (Friedman et 
al., 1992).  The activity of IKKβ and IRS-1 serine312 phosphorylation was assayed 
in vastus lateralis muscle biopsies of post-surgery patients and non-surgery 
controls in the third experiment.  All subjects were female and considered to be in 
good health after filling out a medical history questionnaire.  Subjects were 
informed of potential risks associated with the study and signed an informed 
consent document, which was approved by the East Carolina University 
Institutional Review Board. 
Whole-body insulin sensitivity experiment   
The first experiment consisted of 128 female subjects who were divided 
into four groups.  One group consisted exclusively of post-gastric bypass surgery 
patients who were weight stable at least 12 mo after surgery (BMI ≈ 30).  The 
other three groups of non-surgery subjects were divided according to BMI: 1) 
lean (BMI < 25), 2) weight-matched to post-surgery patients (BMI = 25 to 35), 
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and 3) morbidly obese (BMI > 35).  As mentioned, this first cohort of subjects was 
used to obtain insulin sensitivity data, including fasting insulin and glucose, as 
well as insulin sensitivity with a 3-h intravenous glucose tolerance test (IVGTT) 
(outlined below).   
Muscle glucose transport experiment   
In the second experiment glucose transport was measured in incubated 
muscle strips obtained during elective abdominal surgery.  Subjects were 
recruited into similar BMI groups, namely, lean (BMI < 25), weight-matched 
controls to post-surgery patients (BMI = 25-35), and morbidly obese (BMI >35).  
The data from these groups were then compared to data previously reported 
(Friedman et al., 1992) for five post-surgery subjects in order to compare the 
given groups with post-surgery patients.   
IKKβ activity and IRS1-Ser312 experiment   
The third experiment included 36 subjects who were evenly recruited into 
four groups, similar to the BMI groups mentioned above.  This cohort of subjects 
had a muscle biopsy (vastus lateralis) that was used to obtain all muscle protein 
data.     
Roux-en-Y gastric bypass surgery   
The gastric-bypass surgery was performed as described previously 
(Pories et al., 1992).  Briefly, Roux-en-Y gastric bypass surgery consists of 
surgical reduction in the size of the stomach and bypassing of a portion of the 
proximal small intestine (foregut). 
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Anthropometrics   
Body mass was measured to the nearest 0.1 kg on a digital electronic 
scale. Height was measured to the nearest 0.5 cm with a stadiometer and BMI 
calculated [mass (kg)/height2 (m2)]. 
IVGTT   
Insulin sensitivity was determined by a minimal model analysis using a 3-h 
IVGTT (Bergman, Finegood, & Ader, 1985), as described previously (Houmard et 
al., 1995).  After fasting samples were obtained, glucose (50%) was injected into 
a catheter placed in an antecubital vein at a dose of 0.3 g/kg body mass.  Insulin, 
at a dose of 0.025 U/kg body mass was injected at minute 20.  Blood samples 
were obtained at minutes 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 19, 22, 25, 30, 40, 50, 
60, 70, 80, 90, 100, 120, 140, 160, and 180 and the samples were then 
centrifuged, and plasma transferred and frozen at -80°C for the subsequent 
determination of insulin and glucose.  Insulin was determined with immunoassay 
(Access Immunoassay System, Beckman Coulter, Fullerton, CA) and glucose 
was determined with an oxidation reaction (YSI model 2300 Stat Plus, Yellow 
Springs Instruments, Yellow Springs, OH).  Insulin sensitivity index (SI) was 
calculated by using the minimal model (Bergman et al., 1985); a higher SI 
indicates greater insulin sensitivity. 
Muscle strip incubations   
Human rectus abdominis muscle strip preparation and incubation was 
performed according to the procedure previously described (Dohm et al., 1988).  
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Muscle strips were incubated in the presence (100 nM) or absence of insulin.  2-
deoxy-D-glucose was used at a concentration of 5 mM for 60 min and glucose 
transport was measured as described previously (Dohm et al., 1988).  2-[1,2-
3H(N)]deoxy-D-glucose (30.2 Ci/mmol) was obtained from Du Pont-NEN (Boston, 
MA). 
Muscle IRS-1, pSer312, and IκBα protein content   
A muscle sample was obtained from the vastus lateralis with the 
percutaneous needle biopsy technique.  Biopsy samples were immediately 
frozen in liquid nitrogen.  Frozen muscle samples were homogenized in ice-cold 
lysis buffer [50 mM HEPES, 50 mM Na+ pyrophosphate, 100 mM Na+ fluoride, 10 
mM EDTA, 10 mM Na+ orthovanadate, and protease and phosphatase (1 and 2) 
inhibitor cocktails (Sigma, St. Louis, MO)], followed by addition of 1% triton and 
brief sonication.  After centrifugation for 1 h at 45,000 g at 4°C, supernatants 
were extracted (cytosolic portion) protein content was detected using a BCA 
protein assay (Pierce, Rockford, IL) and individual homogenate volumes were 
adjusted so that precisely 50 µg of protein were loaded into each lane.  For IRS1-
Ser312 and total IRS-1 analysis, 200 µg of homogenates were subjected to 10 µl 
IRS-1 monoclonal IP antibody (Santa Cruz Biotech, Santa Cruz, CA) overnight 
then coupled to protein A sepharose beads and rotated for 2 hours at 4°C 
(Amersham Biosciences, Uppsala Sweden) and washed.  After addition of 
sample buffer, samples were separated by SDS-PAGE using 7.5% or 10% 
Tris·HCl gels and then transferred to PVDF membranes for probing by the 
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following antibodies: rabbit polyclonal IRS-1 and IRS-1 phospho serine312 
purchased from Millipore (Billerica, MA) and IκBα antibodies were purchased 
from Cell Signaling (Beverly, MA).  Following incubation with primary antibodies, 
blots were incubated with appropriate horseradish peroxidase-conjugated 
secondary antibodies.  Horseradish peroxidase activity was assessed with ECL 
solution (Thermo Scientific, Rockford, IL), and exposed to film.  The image was 
scanned and band densitometry was assessed with Gel Pro Analyzer software, 
version 4.2 (Media Cybernetics, Silver Spring, MD).  Content of phospho-proteins 
(using phospho-specific antibodies) was calculated from the density of the band 
of the phospho-protein divided by the density of the protein using the appropriate 
antibody. 
Statistics   
All data are shown as mean ± SE.  Comparisons between the groups with 
insulin sensitivity, muscle protein levels, and muscle glucose transport rates were 
made using one-way ANOVA, followed by post hoc analyses where appropriate.  
Correlations between variables were determined by Dunnette T3 post hoc 
analysis.   
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Results 
Subject characteristics are presented in Table 2.1.  None were taking 
medications that would interfere with metabolism, and all were free from known 
cardiovascular disease and diabetes mellitus, and a few were glucose tolerance 
impaired (fasting glucose > 110 mg/dL; two in the lean group, two in the obese 
group, and five in the weight-matched group).  The mean weight of all gastric 
bypass subjects decreased from 136.6±21.5 to 81.9±13.2 kg (mean±SD, 
P<0.001), resulting in a mean weight loss of 54.7±18.7 kg.  Similarly, BMI fell 
from 48.6±5.7 to 28.8±4.6 kg/m2 (P=0.001).  The BMI of the post-surgery groups 
was not significantly different than the weight-matched control groups.   
Fasting glucose, insulin and insulin resistance (HOMA)   
Average plasma glucose concentration for the post-surgery subjects 
(76±10.2 mg/dl) was lower when compared with all non-surgery control subjects 
(95.3±13.8 mg/dl) (Figure 2.1A; P<0.001).  There was no significant change in 
fasting glucose with increasing BMI in either control or post-surgery groups.  
Fasting insulin concentration and BMI were positively correlated (r =0.598, 
P<0.001) for all non-surgery control subjects.  In contrast, the same correlation in 
post-surgery subjects revealed no significant relationship (r = 0.304, P= 0.169; 
Figure 2.1B).  Fasting glucose and insulin values were used to calculate 
homeostasis model assessment (HOMA) values, an index of insulin resistance.  
HOMA values were significantly related with BMI in the non-surgery subjects 
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(P<0.01, r = 0.283, Figure 2.2A), whereas the post-surgery patients revealed no 
significant correlation.  
Whole-body insulin sensitivity   
The post-surgery group had insulin sensitivity index (SI) values that were 
361% higher than the morbidly obese and 47% higher than weight-matched 
groups (P<0.005 for both; Figure 2.2B).  The post-surgery group’s SI levels were 
not significantly different from the lean group, despite having a greater BMI.  The 
SI value of the morbidly obese was 68% lower than the weight-matched controls, 
suggesting an inverse relationship between whole-body insulin sensitivity and 
BMI (P<0.05).  This is consistent with the positive correlation between BMI and 
HOMA from all non-surgery subjects (Figure 2.2A; P<0.01, r = 0.283).       
Muscle glucose transport   
We previously reported that muscle glucose transport was significantly 
lower in morbidly obese patients than in lean controls (Dohm et al., 1988; 
Friedman et al., 1992).  Additionally, in five gastric bypass patients who 
subsequently had elective abdominal surgery after weight loss, muscle glucose 
transport was not different than that of lean subjects, despite the post surgery 
group having an average BMI of 31 (Friedman et al., 1992).  To determine how 
post-surgery muscle glucose transport compared to a weight-matched control 
group, we retrieved muscle glucose transport measurements from a database of 
our previous experiments (Figure 2.3A).  Previously published post-surgery 
glucose transport values (Friedman et al., 1992) are shown in figure 2.3A for 
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comparison.  Insulin-stimulated glucose transport values were lower in the 
weight-matched group and morbidly obese groups compared to the lean control 
groups (P<0.05).  There were no differences in insulin-stimulated glucose 
transport between the morbidly obese and weight-matched groups.  This is in 
agreement with our previous report that muscle glucose transport is related to 
BMI up to a BMI of 30, after which there is no further change (Elton, Tapscott, 
Pories, & Dohm, 1994); i.e., muscle insulin resistance is maximal at a BMI of 30.  
Post surgery glucose transport values were similar to the lean group and greater 
than morbidly obese and weight-matched subjects.   
We previously reported that insulin-stimulated glucose transport was 
depressed in muscle of morbidly obese patients, compared to lean controls 
(Dohm et al., 1988).  With the larger number of observations in the present data 
set we extend this observation by reporting that basal glucose transport (in the 
absence of insulin) is also lower in muscle of morbidly obese patients.  Also, a 
significant positive relationship was found between the rates of basal and insulin-
stimulated glucose transport (P<0.001, r =0.726, Figure 2.3B).  This suggests 
that the factors that regulate basal glucose might also be those that regulate the 
rate in the presence of insulin.  This was unexpected as we had predicted that 
insulin resistance might only have an effect on insulin-stimulated glucose 
transport.   
 
 
  
33
Insulin sensitivity and IRS1-Ser312   
Inasmuch as serine312 phosphorylation of the IRS-1 protein has been 
implicated in inhibiting insulin signaling, this parameter was investigated in vastus 
lateralis muscle biopsies of lean, weight-matched, morbidly obese, and post-
surgery subjects (group 3 in Table 2.1).  Ser312 phosphorylation of IRS-1 was 
significantly greater in the morbidly obese and weight-matched subjects versus 
the lean and post-surgery subjects (P<0.05).  IRS1-Ser312 phosphorylation 
followed a similar pattern to the insulin-stimulated glucose transport data.  In 
particular, IRS1-pSer312 did not differ between the morbidly obese and weight-
matched groups (Figure 2.4A).  Moreover, IRS1-Ser312 phosphorylation in post-
surgery subjects was significantly reduced by 47% compared with morbidly 
obese (P=0.04) and tended to be lower when compared with the weight-matched 
subjects (P=0.057).   
IκBα and IRS1-Ser312   
Due to the implicated role of IKKβ as a serine kinase of IRS1-Ser312, 
muscle levels of IκBα, a substrate of IKKβ that is rapidly ubiquitinated and 
degraded upon phosphorylation, were measured in an effort to determine IKKβ 
activity (de Alvaro et al., 2004).  Greater IKKβ activity would be evident in 
reduced levels of IκBα.  Similar to our observations with IRS1-phospho-Ser312 
and insulin-stimulated glucose uptake in muscle, IκBα levels in the post-surgery 
subjects were similar to lean, and were significantly elevated by 44% compared 
with the morbidly obese (P<0.05) and 47% compared with the weight-matched 
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controls (P<0.05), which demonstrated increased IKKβ activity in the weight-
matched and morbidly obese compared to the lean and post-bypass subjects 
(Figure 2.4B).  With correlational analysis, we discovered a highly significant 
inverse relationship between IκBα and phospho-Ser312 levels (P=0.003, r =-0.47, 
Figure 2.4C).   
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Table 2.1.  Characteristics of patients/subjects in the three experiments.  
Subject characteristics  
Experiment Age (y) BMI (kg/m
2
) 
Number of 
observations (n) 
 
Experiment 1: Whole-body insulin sensitivity, fasting glucose and insulin 
Lean  
BMI<25 (non-surgery) 38.9 ± 15.0 23.4 ± 1.5 33 
Weight-matched  
BMI 25-35 (non-surgery) 41.8 ± 14.1 28.5 ± 1.7 50 
Morbidly obese  
BMI>35 (non-surgery) 40.3 ± 16.1 47.7 ± 9.5 14 
Post-surgery 43.5 ± 9.8 29.4 ± 4.9 31 
Experiment 2: Muscle glucose transport from rectus abdominis muscle 
taken during surgery 
Lean  
BMI<25 39.3 ± 6.4 22.4 ± 2.1 51 
Weight-matched  
BMI 25-35 42.6 ± 19.0 28.9 ± 2.8 251 
Morbidly obese  
BMI>35 41.6 ± 4.2 46.2 ± 4.0 20 
Experiment 3: Vastus lateralis muscle biopsy for IRS1-Ser
312
 and IκBα 
Lean  
BMI<25 (non-surgery) 35.1 ± 14.4 21.7 ± 1.9 9 
Weight-matched  
BMI 25-35 (non-surgery) 35.5 ± 10.1 30.9 ± 2.7 9 
Morbidly obese  
BMI>35 (non-surgery) 32.8 ± 13.3 44.6 ± 4.2 9 
Post-surgery 40.8 ± 8.1 29.9 ± 4.1 9 
Mean ± SD.  There is no statistical difference in BMI between the  
weight-matched and post-surgery groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
36
 
40
60
80
100
120
140
15 25 35 45 55 65
BMI (kg/m
2
) 
F
a
s
ti
n
g
 G
lu
c
o
s
e
 (
m
g
/d
l)
 
 
Figure 2.1A.  The correlations between BMI and glucose for non-surgery control 
subjects (black circles) and post-surgery patients (white triangles).  The data are 
from experiment 1 patients (see Table 2.1).  The comparison of fasting glucose 
values between non-surgery control subjects (n=97) and post-surgery subjects 
(n=31). 
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Figure 2.1B.  The correlations between BMI and insulin for non-surgery control 
subjects (black circles) and post-surgery patients (white triangles).  The data are 
from experiment 1 patients (see Table 2.1).  Fasting insulin values between non-
surgery subjects and post-surgery subjects.  A positive and significant correlation 
was found (P<0.001, r = 0.598) for the non-surgery subjects.  The same 
correlation in post-surgery subjects revealed no significant relationship (P = 
0.169, r = 0.304).  Data are presented as mean ± SD.   
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Figure 2.2A.  Whole-body insulin sensitivity determined by HOMA correlated 
with BMI.  The data for the HOMA analysis were taken from experiment 1 (see 
Table 2.1).  The comparison of HOMA values for non-surgery control subjects 
(black circles) and post-surgery patients (white triangles).  A positive and 
significant correlation between HOMA and BMI was found (P<0.01, r = 0.283) for 
the non-surgery subjects.  The same correlation in post-surgery subjects 
revealed no significant relationship (P = 0.083, r = 0.446).   
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Figure 2.2B.  Whole-body insulin sensitivity determined by IVGTT for four BMI 
groups.  The data for insulin sensitivity analysis were taken from experiment 1 
(see Table 2.1).  The difference in whole-body insulin sensitivity between BMI 
groups.  *The post-surgery and lean groups are statistically higher (P<0.005) 
than the morbidly obese and weight-matched groups.  †P<0.05 for the 
comparison between the morbidly obese and all other groups.  Data are 
presented as mean ± SD.   
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Figure 2.3A.  2-Deoxy-D-glucose uptake in incubated muscle strips in the 
presence (100 nM) or absence of insulin.  The data were obtained from subjects 
in experiment 2 (see Table 2.1).  A comparison of basal (empty bars) and insulin-
stimulated (filled bars) glucose transport.  *Insulin-stimulated glucose transport in 
the morbidly obese and weight-matched groups was statistically lower (P<0.05) 
than the lean and post-surgery groups.  †Basal glucose transport in the morbidly 
obese and weight-matched groups was statistically lower (P<0.05) than the lean 
and post-surgery groups.  Basal and insulin-stimulated glucose transport in 
muscle from morbidly obese subjects did not differ from the weight-matched 
subjects.   
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Figure 2.3B.  The correlation between basal and insulin-stimulated glucose 
transport in skeletal muscle strips.  The data were obtained from subjects in 
experiment 2 (see Table 2.1).  The correlation between basal and insulin-
stimulated glucose transport revealed a highly significant relationship (P<0.001; r 
=0.726).  Data are presented as mean ± SD.   
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Figure 2.4A.  Muscle levels of IRS1-phospho-Ser312. Non-surgery control 
subjects and post-surgery patients were from experiment 3 (see Table 2.1).  
Western blot analysis of serine312 phosphorylation of IRS1. *P<0.05 for the 
comparison between the lean group and the morbidly obese and weight-
matched. †P<0.05 for the comparison between the post-surgery and the morbidly 
obese groups.  The post-surgery group tended to have a lower level compared 
with the weight-matched group (P =0.057).   
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Figure 2.4B.  Muscle levels of IκBα.  Non-surgery control subjects and post-
surgery patients were from experiment 3 (see Table 2.1).  Western blot analysis 
of IκBα in skeletal muscle between groups.  *P<0.05 for the observation that the 
lean and post-surgery groups were statistically higher than the morbidly obese 
and weight-matched groups.  IκBα levels were similar between post-surgery 
subjects and lean subjects.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
44
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
0.00 0.50 1.00 1.50 2.00
IκBα Protein levels
(A.U.)
p
S
e
r
3
1
2
 (
p
S
e
r
3
1
2
:I
R
S
1
)
(A
.U
.)
 
 
Figure 2.4C.  The correlation between IRS1-pSer312 and IκBα in skeletal muscle. 
Non-surgery control subjects and post-surgery patients were from experiment 3 
(see Table 2.1).  The correlation between IκBα and IRS1-phospho-Ser312 levels 
between non-surgery and post-surgery subjects (P=0.003, r =-0.47).  Data are 
presented as mean ± SD.   
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Discussion 
The primary effect of gastric-bypass surgery in the obese is significant 
weight loss, but an important side effect of the procedure is the dramatic and 
rapid rescuing of insulin sensitivity.  We observed lower fasting glucose and 
insulin values from the post-surgery group compared with all other subjects.  
Further, we found that whole-body insulin sensitivity, as measured by IVGTT, is 
significantly greater in the post-surgery subjects compared with BMI-matched 
control subjects.  Additionally, despite having a significantly higher BMI than the 
lean subjects, post-surgery subjects enjoy comparable SI values.   
We have previously shown that muscle insulin resistance in obese 
individuals is related to depressed insulin signal transduction (Q. Zhou et al., 
1999).  Since phosphorylation of the IRS1-Ser312(human)/307(rodent) residue has been 
implicated in attenuating insulin signal transduction, we measured IRS1-pSer312 
and IκBα protein levels, as a surrogate for IKKβ activity, and found that both IκBα 
and IRS1-phospho-Ser312 protein levels in skeletal muscle from post-surgery 
patients were similar to that seen in muscle from lean subjects despite the post-
surgery group having a significantly higher BMI (Figure 2.4A and 2.4B).  The NF-
κB pathway has garnished a great deal of attention recently in regards to its 
novel effects on metabolic function and substrate utilization.  In particular, IKKβ 
has been studied in a variety of cells, including endothelial, hepatic, and skeletal 
muscle.  Research into the role of the NF-κB pathway in endothelial cells has 
been conducted due, in part, to the pathological consequences of inflammation in 
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the vascular system (Cacicedo et al., 2004; Hattori et al., 2006; Partridge et al., 
2007; Zhang & Frei, 2001).  Recent work by Wu et al. (X. Wu et al., 2007) 
determined that activation of IKKβ by TNF-α is suppressed by adiponectin.  This 
is particularly interesting due to adiponectin’s ability to improve insulin sensitivity 
(Yamauchi et al., 2001).  Further, studying the role of NF-κB pathway proteins in 
the liver, Cai et al. (Cai et al., 2005) revealed that diet-induced obesity in mice 
lead to increased NF-κB pathway signaling in the liver.  Mice with a liver-specific 
constitutively active IKKβ transgene suffered from systemic insulin resistance 
and further analysis revealed a dose-dependent relationship between NF-κB 
activity in the liver and the onset of system insulin resistance.  Moreover, in 
human hepatocytes, Gao et al. (Gao et al., 2002) treated cells with TNF-α and 
found increased IRS1 phosphorylation at Ser312.  This IRS1-Ser312 
phosphoryltaion correlated with the disappearance of IκBα, which represents 
increased IKKβ activity. 
Since skeletal muscle is the main depot for insulin-stimulated glucose 
uptake, studying the effects of IKKβ on insulin signaling in this tissue is 
worthwhile.  A study by de Alvaro et al. (de Alvaro et al., 2004) reported that IKKβ 
activation in rat skeletal muscle cell culture resulted in a significant increase in 
IRS1-Ser307 phosphorylation.  They also explored the role of a pharmacological 
IKKβ inhibitor, salicylate, in preventing IKKβ-induced insulin resistance.  
Targeted disruption of the Ikkβ locus in mice results in lower fasting glucose and 
insulin concentrations, as well as preventing insulin resistance from a high-fat 
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diet.  Similar results have been reported with salicylate treatment (Yuan et al., 
2001).  Additionally, Kim et al. (Kim et al., 2001) employed lipid infusions in 
rodents to cause acute insulin resistance.  They observed that this effect was 
attenuated with pretreatment with salicylates.  Further, lipid infusions performed 
in Ikkb heterozygous knockout mice revealed improvements in insulin sensitivity 
during hyperinsulinemic-euglycemic clamps when compared to controls.   
IKKβ activation, and subsequent IRS1-Ser312 phosphorylation, has been 
shown to be a result of the accumulation of excess fatty acids within the muscle 
that are subsequently partitioned toward storage or the formation of fatty acid 
metabolites, resulting in insulin resistance (Itani et al., 2002; Lee et al., 2006; 
Schmitz-Peiffer, 2002; Todd et al., 2007; C. Yu et al., 2002).  We have previously 
shown that intramyocellular lipid (IMCL) levels are significantly reduced following 
gastric bypass surgery (Gray et al., 2003).  Moreover, Greco et al. (Greco et al., 
2002) determined that surgery-induced weight loss results in a greater-than-
expected reduction in IMCL when compared with diet-induced weight loss alone.  
IMCL depletion is certainly a likely explanation for the improvements we 
observed in post-surgery patients in regards to levels of IκBα and IRS1-pSer312 
due to their role in mediating lipid-induced insulin resistance and it may partly 
explain the differences in whole-body insulin sensitivity.   
Not surprisingly, in control subjects fasting insulin levels and insulin 
resistance (HOMA) have positive relationships with BMI.  However, fasting 
insulin and insulin resistance are not associated with BMI in the post-surgery 
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subjects.  BMI was used as a global assessment of body fat and weight loss in 
the current study.  Whereas BMI is not an accurate indicator of body fat in certain 
populations with relatively greater muscle mass, given that all subjects in the 
current study were sedentary, we feel it is a legitimate measurement.  Moreover, 
in regards to the weight loss and reduction in BMI associated with bypass 
surgery, it has been shown that the tremendous fat loss associated with gastric 
bypass surgery is mostly a result of a reduction in truncal fat (Olbers et al., 2006). 
A possible concern may be the possible confounding effect of a change in 
food intake as a result of gastric bypass surgery, which our group has previously 
explored (Sinha, Perdomo, Brown, & O'Doherty, 2004).  While patients 
experience an acute and meaningful decrease in caloric intake following surgery 
that results in significant weight loss, the outcomes we explored in the current 
study were measured approximately 12 mos following surgery in patients who 
were weight stable on a eucaloric diet, which would seemingly negate any dietary 
effect.   
We interpret our data to suggest that the improvement in insulin sensitivity 
after gastric bypass is not exclusively due to weight loss and may implicate an 
effect of the surgery itself (Pories, 1992).  A comparison of various surgical 
interventions lends support for this hypothesis.  Namely, gastric banding surgery 
restricts food intake but does not change the channel of food flow.  The remission 
rate for gastric banding is 48% while that for gastric bypass is 84% (Buchwald et 
al., 2004).  In addition, Dixon et al. (Dixon et al., 2008) reported that the 
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remission of diabetes was correlated with the degree of weight loss, which is in 
contrast with the data we present here for gastric bypass.  Moreover, Lafèrrere et 
al. (Laferrere et al., 2008) compared subjects who experienced comparable 
levels of weight loss due to hypocaloric diet and surgery.  Whereas both 
interventions result in improved diabetes control, they found that patients who 
underwent bypass surgery enjoyed a better clinical outcome and no longer 
required diabetes medication.   
If the improvement in insulin sensitivity after gastric bypass is not related 
to weight loss, an attractive alternative hypothesis is that increased insulin 
sensitivity and remission of diabetes after gastric bypass is due to restructuring of 
the gastrointestinal tract (Pories, 1992).  According to this hypothesis, bypassing 
a portion of the duodenum and jejunum causes either: 1) decreased secretion of 
a diabetes-inducing peptide (anti-incretin) from the foregut or 2) increased 
secretion of an anti-diabetes peptide (incretin) from the hindgut.  This “foregut 
bypass hypothesis” was first suggested Pories (Pories, 1992) but has only 
recently received attention by Rubino (Rubino, 2008), who, with his colleagues, 
has extensively studied this hypothesis in a non-obese animal model of diabetes 
(GK rat).  They found that a duodenal-jejunal bypass, which does not result in 
food restriction or weight loss, leads to improved glucose tolerance in the diabetic 
GK rat. 
In summary, whole-body insulin sensitivity, as measured by IVGTT, and 
muscle glucose transport following gastric bypass are greater than predicted 
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from the weight-matched control group.  We interpret these findings to suggest 
that the improvement in insulin sensitivity is not a result of weight loss, but is 
more likely related to bypass of the foregut.  Based on our results, we believe 
that IRS1-Ser312 phosphorylation is a potential cause for the insulin resistance 
seen in the weight-matched and morbidly obese compared to the lean group, and 
that gastric bypass appears to result in reduced IRS1-Ser312 phosphorylation to 
levels similar to lean controls.  Finally, we have implicated IKKβ, an NF-κB 
pathway serine kinase, as a potential culprit responsible for phosphorylating 
IRS1-Ser312, and that bypass surgery may indirectly result in reduced IKKβ 
activity in human skeletal muscle. 
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Addendum 
Whereas inflammatory cytokines and NF-κB pathway intermediates inhibit 
insulin signaling, AMPK plays a key role in increasing glucose uptake.  In fact, a 
deficiency in AMPK activity has been implicated in the onset of type 2 diabetes 
(Winder & Hardie, 1999).  AMPK has been shown to prevent cytokine-induced 
NF-κB pathway stimulation and result in reduced IKKβ action (Cacicedo et al., 
2004; Cleasby et al., 2004; Hattori et al., 2006; Hattori et al., 2008), suggesting a 
more direct effect of AMPK on the NF-κB pathway.  Interestingly, AICAR 
treatment  in human myotubes has also been found to decrease cytokine 
production (Lihn et al., 2008).  The purpose of this study was to determine 
whether baseline differences in AMPK activity may account for the differences 
observed in insulin sensitivity between post-bypass patients and control subjects. 
To investigate the reversal of insulin resistance after bypass surgery, in 
phosphorylation state of AMPK was assayed in vastus lateralis muscle biopsies 
of post-surgery patients and non-surgery controls, as described above.  Western 
blot analysis was performed as described above, and antibodies against 
phospho-AMPK and total AMPK were purchased from Cell Signaling 
Technologies (Beverly, MA).  Levels of AMPK phosphorylation were controlled 
for by total AMPK.  AMPK phosphorylation was significantly greater in the post-
bypass group compared with all other groups (P<0.05; Figure 2.5).   
Our hypothesis that baseline differences in AMPK activity explain differences in 
IKKβ action was not supported from the data.  However, the observation that 
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post-bypass patients exhibit elevated AMPK phosphorylation is intriguing and 
worth highlighting.   
A unique characteristic of the post-bypass group is their trend to mirror the 
lean group regarding IKKβ action, IRS1-pSer312, and whole-body insulin 
sensitivity, despite being overweight/obese.  However, in contrast to all previous 
measurements between these groups, AMPK activity, as measured by its 
phosphorylation state, differed drastically in the post-bypass group compared to 
all others.  This finding may reveal a potential pathway through which the muscle 
from post-bypass patients becomes remarkably insulin sensitive.   
The ability of AMPK to prevent lipid-induced insulin resistance has been 
recently explored in skeletal muscle (Fujii et al., 2008).  Namely, Fujii et al. 
(2008) observed reduced insulin receptor-β subunit, IRS-1, and Akt in muscle-
specific transgenic (TG) mice expressing an inactive form of AMPKα2 when fed a 
high-fat diet compared with wild type controls fed the same diet.  Further, 
whereas muscle levels of DAG did not differ between the mice on control diet, 
DAG levels were significantly elevated in TG mice versus control when fed a 
high-fat diet. Moreover, these observations correlated with a reduction in insulin-
stimulated glucose uptake in isolated soleus of TG mice.   
The disparity in phospho-AMPK seen in the post-bypass group may be a 
function of the varying role of AMPK-stimulating hormones that accompany the 
surgery and the subsequent tremendous weight loss.  In particular, adiponectin is 
a hormone released from the adipocytes that has been shown to stimulate AMPK 
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activity in skeletal muscle (Hardie, 2004) and circulating levels of adiponectin 
have been shown to be elevated following gastric bypass (de Carvalho et al., 
2008; de la Torre et al., 2008).  Moreover, lifestyle intervention in individuals 
suffering from type 2 diabetes also elicits a significant improvement in 
adiponectin levels.  Together these findings possibly suggest that increased 
adiponectin, and subsequent AMPK stimulation, may be an adaptive mechanism 
whereby formerly insulin-resistant muscle becomes more insulin sensitive.   
An alternative explanation regarding the elevations in phospho-AMPK 
observed in the post-bypass group may be a function of reduced stomach 
volume and a heightened sensitivity to fasting in the post-bypass group.  AMPK 
has been shown to mediate a host of adaptations in skeletal muscle during 
fasting to promote fatty acid oxidation, including elevated expression of CD36 
and CPT1, which would encourage fatty acid flux into the cell and shuttling into 
the mitochondira (Long et al., 2005; Long & Zierath, 2008).  Muscle biopsies 
were pulled from subjects following an overnight fast.  Due to the drastically 
reduced stomach volume of the post-bypass patients, it is highly possible that 
these subjects eat relatively less during the final meal on the night preceding the 
biopsy and are subsequently in a greater state of nutrient deprivation the 
following day.  Further, this heighted sensitivity to fasting may be sensed in 
skeletal muscle and AMPK is activated in response.   
In summary, we provide data that AMPK phosphorylation is elevated in 
the muscle of post-bypass patients compared with control subjects.  We believe 
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this may be an adaptive mechanism that is partly responsible for the 
improvements in insulin signaling and glucose tolerance.  Moreover, we offer the 
explanations that this effect may result from elevated circulating adiponectin 
and/or heighted sensitivity to fasting, both of which stimulate AMPK activity in 
skeletal muscle. 
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Figure 2.5.  Differences in pAMPK:AMPK in post-surgery patients and 
controls.  Post-surgery patients had significantly greater pAMPK levels than all 
other groups.  *p<0.05 for the comparison between Post Surgery and all other 
groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Chapter Three 
 
Metformin Improves Insulin Signaling in Obese Rats via Reduced IKKβ 
Action in a Fiber-type Specific Manner 
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Abstract 
Metformin is a widely used insulin-sensitizing drug, though its mechanisms 
are not fully understood.  Metformin has been shown to activate AMPK in a 
variety of tissue, including skeletal muscle; however, its effects on the inhibitor of 
κB kinaseβ (IKKβ) in this same tissue are unknown.  The aim of this study was to 
1) determine the ability of metformin to attenuate IKKβ, 2) determine whether 
changes in AMPK activity are associated with changes in IKKβ action in skeletal 
muscle, and 3) examine whether changes in AMPK and IKKβ are consistent with 
increased insulin sensitivity and reduced phosphorylation of IRS1-Ser307.  Lean 
and obese Zucker male rats received either vehicle or metformin by oral gavage 
daily for four weeks (four groups of eight) followed by an oral glucose tolerance 
test (OGTT).  All proteins were measured in white gastrocnemius (WG), red 
gastrocnemius (RG), and soleus.  Metformin treatment reduced OGTT area 
under the curve for both glucose and insulin values in the obese rodents only 
(P<0.05), indicating improved insulin sensitivity.  AMPK activation, determined by 
phosphorylation state, increased (P<0.05) in WG in both lean (57%) and obese 
(106%).  Further, metformin increased IκBα levels in both WG (150%) and RG 
(67%) of obese rats, indicative of reduced IKKβ activity (P<0.05), and was 
associated with reduced IRS1-pSer307 (30%) in the WG of obese rats (P<0.02).  
From these data we conclude that metformin treatment appears to exert an 
inhibitory influence on skeletal muscle IKKβ activity, as evidenced by elevated 
  
58
IκBα levels and reduced IRS1-Ser307 phosphorylation in a fiber-type specific 
manner.   
Keywords: insulin signaling, AMPK, IKKβ, Zucker rat 
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Introduction 
 
Insulin resistance is considered a characteristic feature of a clustering of 
diseases referred to often as the metabolic syndrome (Grundy, Brewer, 
Cleeman, Smith, & Lenfant, 2004).  Such associated pathologies include not only 
cardiovascular disease but also Type II Diabetes Mellitus and, more recently, 
inflammatory-related metabolic diseases.   In this regard, obesity is often 
associated with insulin resistance, notably in skeletal muscle (Arkan et al., 2005; 
Perseghin, Petersen, & Shulman, 2003).  This has immense clinical and 
economic significance as obesity has reached epidemic proportions not only in 
the U.S., but in Western Society at large (Mokdad, Marks, Stroup, & Gerberding, 
2004).  Although increased physical activity and nutritional interventions have 
been used to reduce the progression or reverse obesity (and hence improve 
insulin action), it has often been met with limited success due to low, long-term 
patient compliance.  These circumstances leave pharmacological interventions 
as an attractive adjunct or alternative therapeutic intervention not only for treating 
obesity but also associated type II diabetes.  Currently, the insulin-sensitizing 
drug metformin, a member of the biguanide drug class, is widely prescribed.  
Despite its widespread prescription however, its basic mechanism of action is 
poorly understood, slowing the development of even more effective insulin-
sensitizing molecules.  
The link between obesity and insulin resistance can be partly explained by 
the NF-κB pathway and its associated upstream kinases, whose activity is 
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stimulated as a result of the chronic and excessive lipid circulation and 
accumulation in non-adipose tissue sites, a prominent feature of obesity (Kahn & 
Flier, 2000; Wellen & Hotamisligil, 2005).  Lipid accumulation in skeletal muscle 
has been shown to be associated with insulin resistance (McGarry, 2002), and 
weight loss appears to reverse this effect (Gray et al., 2003).  Ectopic fat 
deposition can lead to activation of the inhibitor of κB kinase β (IKKβ) and 
induction of its downstream substrate, the inflammatory transcription factor NF-
κB (Arkan et al., 2005).  Specifically, NF-κB is sequestered in the cytoplasm in an 
inactive state while complexed with the inhibitor protein called inhibitor κBα 
(IκBα).  Upon stimulation by IKKβ, which is itself stimulated by both cytokines 
and lipids (Hotamisligil, 2006), IκBα is phosphorylated and degraded, resulting in 
the liberation of NF-κB, which migrates into the nucleus and activates 
transcription of inflammatory cytokine genes.  Interestingly, in addition to 
activating NF-κB, IKKβ has also been shown to directly phosphorylate serine312 
(Human)/307(rodent) on insulin receptor substrate (IRS)-1, leading to a decrease in 
insulin signal transduction (Cai et al., 2005; Ghanim et al., 2001; Perseghin et al., 
2003; Yuan et al., 2001).   
In contrast to the insulin-resistant effects of excessive IKKβ activity, AMP-
activated protein kinase (AMPK), a prominent metabolic enzyme, acts to improve 
insulin sensitivity, potentially counter-acting the deleterious effects of lipid 
excess.  Additionally, many commonly prescribed anti-diabetic medications, such 
as metformin and the thiazolidinediones, are known to increase AMPK activity 
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(Lessard et al., 2006; Suwa, Egashira, Nakano, Sasaki, & Kumagai, 2006).  In 
the past few years, research has revealed the role of AMPK as an inhibitor of 
IKKβ activity in certain cell types.  AMPK has been shown to inhibit both fatty 
acid- and TNFα-induced increases in IKKβ activity in cultured endothelial cells 
(Cacicedo et al., 2004; Hattori et al., 2006), macrophages (Jhun et al., 2004), and 
astrocytes (Giri et al., 2004).  Furthermore, metformin treatment has also 
displayed anti-IKKβ properties in the liver and has been shown to prevent lipid-
induced insulin resistance.  Namely, Cleasby et al. (Cleasby et al., 2004) 
observed elevated levels of IκBα, indicative of reduced IKKβ activity, in liver from 
metformin-treated rodents.   
Inasmuch as skeletal muscle is the main consumer of glucose in vivo, 
studying the effects of metformin on IKKβ activity in skeletal muscle, and the role 
of AMPK in possibly mediating this response, holds great potential for addressing 
the obesity-diabetes relationship in skeletal muscle.  Metformin has been shown 
to upregulate AMPK activity in both human and rat skeletal muscle (Musi, 2006; 
Suwa et al., 2006).  Work in endothelial cells and liver has shown that metformin 
can reduce IKKβ activity, raising the possibility that activation of AMPK may be a 
mechanism by which metformin improves insulin sensitivity in skeletal muscle.  
Therefore, the aim of this study was to 1) determine whether metformin 
attenuates IKKβ activity in skeletal muscle of obese rats, 2) determine whether 
changes in AMPK are associated with reduced IKKβ activity in skeletal muscle, 
and 3) examine whether a decrease in IKKβ activity coincides with reduced 
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phosphorylation of Ser307 on IRS1 in skeletal muscle and whether this translates 
into increased glucose tolerance.   
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Materials and Methods 
Materials   
All antibodies used in this investigation were obtained from commercial 
sources.  Anti-rabbit monoclonal IRS-1 IP antibody for immunoprecipitation was 
purchased from Santa Cruz Biochtech (Santa Cruz, CA).  IRS-1 and  Phospho-
IRS1 Ser307 antibodies were purchased from Millipore (Billerica, MA).  Antibodies 
for phospho-AMPKα, and AMPKα were purchased from Cell Signaling 
Technologies (Beverly, MA) and IκBα from Santa Cruz Biochtech (Santa Cruz, 
CA).  Horseradish peroxidase-conjugated anti rabbit secondary antibodies were 
purchased from Cell Signaling Technologies (Beverly, MA).   
Animals and housing 
All protocols for animal use were approved by the Animal Care and Use 
Committee at East Carolina University.  Lean and obese male Zucker rats were 
obtained from Harlan (Indianapolis, IN) and were housed under controlled 
temperature (23 °C) and lighting (12 hours of light, 0600-1800 hours; 12 hours of 
dark; 1800-0600 hours) with free access to water and standard rat chow.  
Animals were fasted 10 h before the oral glucose tolerance tests (OGTT).  
Metformin treatment and oral glucose tolerance testing    
Obese and lean Zucker rats were randomly assigned to receive either 
control (saline) or metformin (320 mg/kg/day) by daily gavage for four weeks 
(N=8 per group) with the final dose given 4 h prior to sacrifice.  At the end of the 
fourth week, an OGTT (2 g/kg BW by oral gavage of dextrose) was performed on 
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each animal.  Blood glucose (glucose oxidase method, One Touch Ultra glucose 
analyzer; Lifescan, Milpitas, CA) and insulin levels (ELISA kit, Linco Research, 
St. Charles, MO) were determined in the fasting condition and at time 30, 60, and 
120 min after dextrose administration (data was expressed as area under each 
curve).  On experimental days, rats were anesthetized with 0.1 ml/100 g body wt 
of a mixture containing 90 mg/ml ketamine and 10 mg/ml xylazine.  With blood 
flow intact, white gastrocnemius (WG), red gastrocnemius (RG), and soleus 
muscles were harvested from hind limbs.  Samples were rapidly dissected, 
cleaned, and frozen within seconds in liquid nitrogen and stored at -80º C until 
analysis.    
Preparation of skeletal muscle homogenates   
Frozen muscle samples (50-80 mg) were homogenized in ice-cold lysis 
buffer [50 mM HEPES, 50 mM Na+ pyrophosphate, 100 mM Na+ fluoride, 10 mM 
EDTA, 10 mM Na+ orthovanadate, 1% Triton X-100, and protease and 
phosphatase (1 and 2) inhibitor cocktails (Sigma, St. Louis, MO)].  Homogenates 
were sonicated for 10 sec then rotated for 2 h at 4 C.  After centrifugation for 25 
min at 15,000 g, supernatants were extracted and protein content was detected 
using a BCA protein assay (Pierce, Rockford, IL) and individual homogenate 
volumes were separated into 50 µg of protein before being frozen in liquid 
nitrogen and stored at -80 C until used for immunoblotting. 
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Immunoblotting   
For IRS-1, homogenates were subjected to 10 µl IRS-1 monoclonal IP 
antibody (Santa Cruz Biotech, Santa Cruz, CA) overnight then coupled to protein 
A sepharose beads and rotated for 2 hours (Amersham Biosciences, Uppsala 
Sweden) and eluted with sample buffer.  Samples were separated by SDS-PAGE 
using 7.5% or 10% Tris·HCl gels and then transferred to PVDF membranes for 
probing by appropriate antibodies.  Following incubation with primary antibodies, 
blots were incubated with appropriate horseradish peroxidase-conjugated 
secondary antibodies.  Horseradish peroxidase activity was assessed with ECL 
solution (Thermo Scientific, Rockford, IL), and exposed to film.  The image was 
scanned and band densitometry was assessed with Gel Pro Analyzer software 
(Media Cybernetics, Silver Spring, MD).  Content of phospho-proteins (using 
phospho-specific antibodies) was calculated from the density of the band of the 
phospho-protein divided by the density of the protein using the appropriate 
antibody. 
Statistical analysis   
All data are presented as means ± SEM.  Two-way analysis of variance 
(ANOVA) was used to compare group and treatment (SPSS, Chicago, IL).  
Where an interaction was observed, post hoc analysis (Bonferroni and Tukey’s 
HSD) was used to determine significance.  Correlation analysis was performed 
by the Pearson product-moment method.  Significance level was established a 
priori at P ≤ 0.05.   
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Results 
Glucose tolerance   
OGTTs were performed to determine glucose tolerance before and after 
treatment and area under the curve (AUC) was used to compare results.  No 
difference in glucose or insulin AUC was observed in the lean control versus 
metformin-treated rodents.  However, both glucose and insulin AUC were 
significantly reduced in the obese rats as a result of the 4-week metformin 
treatment (Figure 3.1; P<0.05). 
Metformin and AMPK activation   
AMPK activation was determined by measuring phosphorylation of AMPK 
and its substrate acetyl-CoA-carboxylase (ACC) while controlling for total levels 
of both proteins.  No difference in AMPK activation was observed in the controls 
between lean and obese in any of the three muscles.  Moreover, chronic 
metformin treatment did not significantly affect AMPK phosphorylation in RG or 
soleus in either the lean or obese rodents (Figure 3.2A), and this was further 
evident by no change in levels of pACC in these muscles (Figure 3.2B).  In 
contrast, metformin resulted in a significant increase in both phosphorylation of 
AMPK and ACC in both the lean (57% for pAMPK and 525% for pACC) and 
obese (106% for pAMPK and 710% for pACC) rats in WG compared with control 
animals (Figures 3.2A and B; P<0.05). 
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Metformin and IκBα   
Inasmuch as metformin has been shown to reduce IKKβ activity in various 
tissues, IκBα was measured as an indicator of IKKβ activity.  No differences in 
IκBα levels were observed between controls animals in either soleus or RG and 
chronic metformin treatment resulted in no significant effect in soleus from the 
lean or obese animals (Figure 3.3A).  However, IκBα levels were significantly 
lower in WG of obese when compared with lean.  Further, metformin treatment 
increased IκBα levels in both RG and WG of obese animals by 67% and 150%, 
respectively, to a level similar to that seen in lean (P<0.05 for RG, P<0.005 for 
WG).  When combining all data from WG, IκBα showed a strong correlation to 
AMPK phosphorylation (r =0.755, P<0.005, Figure 3.3B).   
IRS1-Serine307 phosphorylation   
Due to the implicated role of serine phosphorylation of IRS1 in inhibiting 
insulin signaling, we measured IRS1-pSer307 and controlled for total IRS1.  
Similar to our observation with IκBα, there was no significant effect of treatment 
on pSer307 levels soleus in either lean or obese rodents (Figure 3.4A).  Similarly, 
no differences were observed in RG, although pSer307 in obese tended to be 
lower in the metformin-treated vs control animals (P=0.061).  In contrast, pSer307 
levels in control animals were significantly higher in obese WG compared with 
lean (P<0.05).  Moreover, pSer307 levels were significantly reduced (30%) with 
metformin treatment in WG from obese rodents (P<0.05), which follows results 
from the OGTT.  Inasmuch as IκBα and pSer307 appeared to follow similar trends 
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in WG, we performed a correlation analysis between the two variables.  When 
comparing pSer307 and IκBα in all groups, no significant correlation was observed 
(R=-0.536, P=0.067).  However, in WG alone the correlation between pSer307 and 
IκBα reached significance (r =-0.789, P<0.01), suggesting an inverse relationship 
in WG (Figure 3.4B).   
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Figure 3.1.  Area under the curve (AUC) from an oral glucose tolerance test 
performed on obese and lean male Zucker controls following 4 weeks of 
metformin treatment.  *P<0.05.  Metformin treatment in the obese rats improved 
glucose tolerance compared with control.       
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Figure 3.2A.  The effect of vehicle (open bars) or metformin (filled bars) on 
AMPK phosphorylation in soleus, RG, and WG.  *P<0.05.  AU, arbitrary units. 
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Figure 3.2B.  The effect of vehicle (open bars) or metformin (filled bars) on ACC 
phosphorylation in soleus, RG, and WG.  *P<0.05.  AU, arbitrary units. 
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Figure 3.3A.  The effect of vehicle (open bars) or metformin (filled bars) on IκBα 
levels in soleus, RG, and WG.  P<0.05 for vehicle vs. metformin treatment within 
same phenotype (*) and lean vs. obese within a given treatment (#).   
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Figure 3.3B.  The correlation between AMPK and IκBα in WG from obese and 
lean male Zucker rats.  AMPK activation and IκBα levels were significantly 
correlated in WG (r =0.755, P<0.005).   
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Figure 3.4A.  The effect of vehicle (open bars) or metformin (filled bars) on IRS1-
pSer307 in soleus, RG, and WG.  P<0.05 for vehicle vs. metformin treatment 
within same phenotype (*) and lean vs. obese within a given treatment (#).   
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Figure 3.4B.  The correlation between IκBα and IRS1-pSer307 in WG from obese 
and lean Zucker male rats.  IκBα and IRS1-pSer307 levels were significantly 
related in WG (R=-0.789, P<0.01). 
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Discussion 
The main finding of the present study is that the beneficial effects of 
metformin treatment on glucose tolerance in obese, insulin resistant rodents is 
associated not only with an elevation in AMPK activity, but also IκBα levels in 
WG from obese, insulin-resistant rats.  This finding is an indication of reduced 
IKKβ activity and suggests that metformin treatment is able to reduce IKKβ 
activity and restore IκBα protein levels within the muscle.  Moreover, these 
observations are associated with improved insulin signaling, as evidenced by 
reduced IRS1-pSer307 levels.  Finally, levels of IκBα and IRS1-Ser307 were 
significantly and inversely correlated with metformin-treated obese rats, but only 
in white muscle, suggesting a fiber-type specific action of metformin on the IKKβ 
signaling pathway.    
Recent work has effectively established the role of IKKβ as an inhibitor of 
insulin action that results in insulin resistance.  In particular, salicylate is known to 
inhibit the activity of IKKβ, and pretreatment of salicylate in lipid-infused rats 
rescues glucose tolerance back to similar levels seen in control rats when 
compared with lipid infusion alone (Yin et al., 1998).  Further, Yuan et al. (Yuan 
et al., 2001) showed that Ikkβ+/- mice have lower fasting glucose and insulin 
concentrations compared to Ikkβ+/+ littermates when on high-fat diets.  
Additionally, IKKβ KO mice experience no decrement in insulin sensitivity in 
response to lipid infusion compared to control mice (Kim et al., 2001).  
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Collectively, these findings demonstrate that activation of IKKβ is associated with 
a negative impact on insulin sensitivity. 
Contrary to the reduced insulin sensitivity associated with IKKβ activity, 
AMPK plays a key role in improving glucose handling and increasing insulin 
action.  In muscles from sedentary rats, co-incubation with insulin and the 
compound 5-aminoimidasole-4-carboxamide-1-β-D-ribofuranoside (AICAR; an 
AMP-mimetic and AMPK activator) has been shown to induce a twofold greater 
glucose uptake compared to insulin alone (Fisher et al., 2002).  Similarly, AICAR-
perfused rat hindlimbs have been shown to increase glucose uptake compared 
with controls (Merrill et al., 1997).   
Research investigating the novel role of AMPK as a mediator in IKKβ’s 
ability to inhibit IRS-1 function in endothelial cells has revealed that AMPK 
inhibits both fatty acid- and TNFα-induced increases in NF-κB in cultured 
endothelial cells (Cacicedo et al., 2004).  When endothelial cell cultures were 
incubated with palmitate, inflammatory markers increased, but this response was 
attenuated in the presence of AICAR.  Moreover, AICAR acted to prevent NF-κB 
activation in the presence of TNFα.  This provides strong evidence in support of a 
role for AMPK in attenuating inflammation and associated cellular metabolic 
dysfunction.  Additionally, metformin, which leads to AMPK activation, dose-
dependently inhibits TNFα-induced NF-κB activation, whereas blocking signaling 
through AMPKα1 (via small interfering RNA) attenuates metformin- and AICAR-
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induced inhibition of NF-κB activation by TNFα, further supporting a role for 
AMPK attenuating the inflammation response (Hattori et al., 2006).   
Research involving metformin has also displayed anti-IKKβ properties in 
the liver.  Cleasby et al. (Cleasby et al., 2004) observed elevated levels of IκBα in 
liver from metformin-treated rodents, providing indirect evidence that AMPK may 
be serving as an IKKβ inhibitor in an insulin sensitive tissue.   These findings 
provide the rationale for exploring the potential role of AMPK as an IKKβ inhibitor 
in skeletal muscle inasmuch as muscle represents the main site of insulin-
dependent glucose uptake. 
  The idea of AMPK attenuating inflammatory activity in skeletal muscle has 
only recently been investigated and, due to a scarcity of data, a consensus has 
yet to be reached.  For example, Steinberg et al. (Steinberg et al., 2006) 
observed that muscle cells with constitutively active AMPK were protected from 
TNFα-induced suppression of insulin-stimulated glucose uptake (TNFα has been 
shown to elicit an increase in IKKβ activity).  In ob/ob mice, it was found that 
AMPK activity was significantly reduced compared with lean controls and that 
TNFα neutralization in ob/ob mice restored AMPK activity to that of lean controls.  
Furthermore, obese mice exhibited reduced fatty acid oxidation, a defect that 
was not observed following TNFα neutralization.  Lastly, ob/ob mice lacking a 
functional TNFα receptor (TNF -/-) enjoy greater insulin sensitivity than control 
ob/ob mice.  It was observed that AMPK activity was higher in obese TNF -/- 
relative to obese controls.  Whereas the evidence provided by Steinberg et al. 
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(Steinberg et al., 2006) places inflammatory mediators upstream of AMPK, the 
work by Hattori et al. (Hattori et al., 2006) offer the opposite perspective—that 
AMPK inhibits NF-κB pathway activity.  Moreover, the observations of the current 
study extend the work by Hattori et al. (Hattori et al., 2006) in that we provide 
evidence that AMPK may attenuate IKKβ activity in skeletal muscle.  In 
conjunction with improved glucose tolerance, we observed an increase in AMPK 
phosphorylation, an increase in IκBα levels (suggesting reduced IKKβ activity), 
and, finally, reduced levels of IRS1-pSer307 in white muscle from metformin-
treated obese rats. 
 In contrast, Ho et al. (Ho et al., 2005) explored the effects of AICAR-
stimulated AMPK activation in rats in vivo and found no reduction in IKKβ 
phosphorylation 60 min following an intraperitoneal injection of AICAR despite a 
robust increase in AMPK activity in skeletal muscle.  Further, they did not 
observe any change in IKKβ phosphorylation in isolated rat EDL muscles treated 
with AICAR.  These findings appear to indicate that AMPK does not directly 
regulate IKKβ activity; however, the acute nature of the study design must be 
considered.  The findings of the current study utilized a chronic treatment 
intervention and support the possibility that metformin-mediated activation of 
AMPK attenuates IKKβ activity, as has been established in hepatic tissue 
(Cleasby et al., 2004).   
Interestingly, metformin-mediated activation of AMPK occurs in the 
absence of any changes in ATP/ADP ratio, indicating that a decrease in cellular 
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energy charge is not the link between metformin and AMPK activation (Hawley, 
Gadalla, Olsen, & Hardie, 2002).  In this regard, synergistic or independent 
mechanisms should also be considered.  For example, metformin has also been 
shown to partially inhibit mitochondrial complex I and subsequent free radical 
production (Owen, Doran, & Halestrap, 2000), raising the possibility that an 
additional, unique effect of metformin in improving IκBα and IRS1-pSer307 levels 
may be related to its effects on mitochondrial function in addition to that of AMPK 
activation.  An association between free radical production, IKKβ activity and 
insulin sensitivity has been established and might prove to be a fruitful area of 
investigation on this topic.      
It is noteworthy that we observed neither an increase in AMPK activity nor 
a reduction in IKKβ activity or IRS1-pSer307 in soleus with metformin treatment.  
Similarly, no differences were noted in either AMPK or IRS1-pSer307 levels in RG, 
although IκBα levels increased in obese RG with metformin treatment.  The 
singular change in IκBα levels without an accompanying reduction in IRS1-Ser307 
phosphorylation in RG was unexpected, though the comparison of IRS1-pSer307 
levels between metformin-treated and control obese animals did approach 
statistical significance (P=0.061).  Future studies seem warranted then to 
determine if both statistical and physiological significance would be realized in 
red muscle following a longer treatment time as would be expected in human 
subjects under chronic metformin prescription. 
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In contrast to the observations in soleus and RG, AMPK, IκBα, and IRS1-
pSer307 levels were all affected by chronic metformin treatment in WG from the 
obese rats.  Specifically, metformin treatment increased AMPK activity and was 
associated with both an increase in IκBα protein levels and a reduction in IRS1-
pSer307.  In accordance with these findings, it should be recognized that 
differences in the IKKβ signaling pathway between muscle fiber types have been 
noted by other investigators.  For example, Bhatt et al. (Bhatt, Dube, Dedousis, 
Reider, & O'Doherty, 2006) observed a reduction in IκBα levels (increase in IKKβ 
activity) with diet-induced obesity in rat skeletal muscle in a fiber-type dependent 
manner.  Specifically, obesity was associated with decreased levels of IκBα in 
superficial vastus (white, fast twitch-glycolytic), whereas the soleus (red, slow 
twitch-oxidative) appeared to be protected from such an effect.  Additionally, 
Iglesias et al. (Iglesias, Furler, Cooney, Kraegen, & Ye, 2004) observed an 
AICAR-induced improvement in glucose uptake in white muscle that was not 
evident in red muscle.  Inasmuch as metformin may exert its action by altering 
mitochondrial function, it is possible that given red muscle’s prevalence of 
mitochondria, a greater metformin dose is required to elicit the same response as 
observed in white muscle.     
 In summary, these findings demonstrate that IRS1-Ser307 phosphorylation 
is elevated in certain muscle types of obese, highly insulin resistant Zucker rats.  
Moreover, metformin treatment improves glucose tolerance in the obese Zucker 
rats, and this treatment effect is associated with increased AMPK activity and 
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reduced IKKβ activity, at least in white muscle.  These findings are novel, in that 
they offer support for the hypothesis that AMPK may be upstream of IKKβ and 
that under the experimental conditions present in the current study, AMPK 
appears to exert an inhibitory effect on IKKβ in a fiber-type dependent manner 
which contributes to the change in muscle insulin signaling and whole-body 
glucose tolerance.  Future studies investigating dose and treatment time for 
metformin seem warranted when considering potential effects on the IKKβ 
signaling pathway in muscles of red fiber type composition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Chapter Four 
 
Lipid-induced Insulin Resistance is Prevented in Lean and Obese Myotubes 
by AICAR Treatment 
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Abstract 
 The molecular mechanisms of obesity-associated insulin resistance are 
becoming increasingly clear and the effects of various lipid molecules, such as 
diacylglycerol and ceramide, on the insulin signal are being actively explored.  To 
better understand the divergent response to lipid exposure between lean and 
obese, we incubated primary human muscle cell cultures from lean (BMI < 25 
kg/m2) and morbidly obese (BMI > 40 kg/m2) subjects with the saturated fatty 
acid palmitate.  Additionally, given that AMPK-activating drugs are widely 
prescribed for their insulin-sensitizing effects, we sought to determine whether 
AICAR-stimulated AMPK activity could prevent or reverse the deleterious effects 
of lipid on insulin signaling.  We found that palmitate incubation for 1 h in lean 
myotubes reduced (p<0.05) IκBα mass, elevated IRS-1 Ser312 phosphorylation, 
and decreased insulin-stimulated phosphorylation of Akt and AS160 and that 
AICAR inclusion prevented these effects.  Moreover, in contrast to the lean, we 
observed that myotubes from morbidly obese individuals appear to be largely 
resistant to the detrimental effects of 16-h lipid exposure as was evident by the 
absence of a reduction in insulin-stimulated IRS-1 Tyr phosphorylation, phospho-
Akt, and phospho-AS160 (p<0.05).  Further, lipid exposure significantly reduced 
IκBα levels and increased IRS1-pSer312 in lean myotubes only (p<0.05).  Despite 
a divergent response to lipid between lean and obese myotubes, AICAR 
inclusion improved insulin signaling in myotubes from lean and morbidly obese 
subjects.  These findings suggest an important role for regular exercise in 
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addition to offering a potential mechanism of action for oral AMPK-activating 
agents, such as TZDs and metformin. 
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Introduction 
Skeletal muscle is the main site of insulin-mediated glucose uptake and it 
has been shown that skeletal muscle is the principal site for peripheral insulin 
resistance (Shulman et al., 1990).  Moreover, it is well established that 
intramyocellular lipid accumulation is associated with insulin resistance 
(McGarry, 2002).  Our group has previously demonstrated that obesity is 
associated with reduced insulin sensitivity (Dohm et al., 1988) and that weight 
loss, through both lifestyle intervention (Houmard et al., 2004) and surgery 
(Bikman et al., 2008; Gray et al., 2003; Houmard et al., 2002), reduces 
intramuscular lipid and improves insulin sensitivity in humans.  Additionally, lipid 
metabolites such as ceramide and diacylglycerol (DAG) have been shown to 
inhibit insulin signaling in a variety of tissue, including liver (Kolak et al., 2007) 
and skeletal muscle (Chavez et al., 2003; C. Yu et al., 2002).   
The precise mechanism through which lipid interrupts the insulin signaling 
cascade is unclear, however a likely candidate is serine phosphorylation of the 
insulin receptor substrate (IRS)-1 (Cai et al., 2005; Yuan et al., 2001) possibly 
through the actions of novel lipid-sensitive protein kinase C isoforms (Griffin et 
al., 1999; Schmitz-Peiffer, 2002; C. Yu et al., 2002), c-jun-N-terminal kinase 
(JNK) (Aguirre et al., 2002; de Alvaro et al., 2004; Ropelle et al., 2006) and the 
inhibitor of κB kinase β (IKKβ) (Arkan et al., 2005; Cai et al., 2005; Kim et al., 
2001; Sinha et al., 2004; Yuan et al., 2001), which are activated by lipid 
metabolites (Schmitz-Peiffer, 2002; C. Yu et al., 2002).   
  
87
Both obesity and insulin resistance are associated with an increased low-
grade inflammatory tone, as evidenced by increased levels of proinflammatory 
cytokines as well as greater activity of the inflammatory factor, NF-κB (Bastard et 
al., 2006; Festa et al., 2001; Permana et al., 2006; Warnberg & Marcos, 2008), 
which is responsible for the transcription of multiple cytokines (including TNF-α 
and IL-1β) (Granger et al., 2004; Piva et al., 2006).  IKKβ is also a prominent 
mediator in the NF-κB pathway through its actions on the NF-κB inhibitor IκBα.  
Briefly, IκBα is phosphorylated by IKKβ, which results in the rapid degradation of 
IκBα and subsequent migration of NF-κB into the nucleus.   
A host of insulin-sensitizing drugs have been shown to act, in part, through 
inhibition of NF-κB pathway activity, including  salicylate (Kim et al., 2001), 
thiazolidinediones (TZDs)(Ghanim et al., 2001; LeBrasseur et al., 2006; Todd et 
al., 2007), and metformin (Cleasby et al., 2004; G. Zhou et al., 2001).  
Interestingly, evidence indicates that both TZDs and metformin increase activity 
of the AMP-activated protein kinase (AMPK) (Fryer, Parbu-Patel, & Carling, 
2002; LeBrasseur et al., 2006; Lessard et al., 2006; Ye et al., 2006).  AMPK is 
ubiquitous in mammalian cells and is considered the ‘fuel gauge’ of the cell, 
responding when cellular energy status is threatened, such as a decrease in ATP 
concentration, by induction of catabolic ATP-generating processes and inhibition 
of synthetic (ATP-consuming) processes  (Winder, 2001).  By stimulating the 
mitochondrial oxidation of fatty acids (Ferre et al., 2003; McGarry, 2002), AMPK 
likely prevents the accumulation of lipid metabolites that activate NF-κB pathway 
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intermediates and disrupts insulin signal transduction (Fediuc et al., 2008).  
However, AMPK has also been shown to prevent cytokine-induced NF-κB 
pathway stimulation and result in reduced IKKβ action (Cacicedo et al., 2004; 
Cleasby et al., 2004; Hattori et al., 2006; Hattori et al., 2008; Lihn et al., 2008), 
suggesting a more direct effect of AMPK on the NF-κB pathway.   
Our lab has previously shown that incubation with saturated fatty acid 
evokes insulin resistance via reduced signaling in primary muscle cells cultured 
from lean individuals (Bell et al., unpublished data).  In addition, we observed that 
insulin signaling was blunted in cultured muscle cells from morbidly obese 
individuals, compared to lean controls (Bell et al., unpublished data).  In the 
present study we more deeply explore the result of various palmitate incubation 
periods in human myotubes from lean and morbidly obese subjects in regards to 
its effect on insulin signaling.  Additionally, given the widely prescribed use of oral 
AMPK activators in diabetes treatment, we examine whether AICAR-induced 
AMPK activation mitigates and/or prevents the deleterious effects of lipid on 
insulin signaling. 
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Materials and Methods 
Subjects   
Lean (n=8; BMI < 25 kg/m2) and morbidly obese (n=8; BMI > 40 kg/m2) 
Caucasian women were recruited for participation in the current study.  All 
subjects were considered sedentary, weight stable, and in good health after filling 
out a medical history questionnaire.  None suffered from metabolic disease, such 
as type 2 diabetes mellitus.  Subjects were informed of potential risks associated 
with the muscle biopsy and signed an informed consent document, which was 
approved by the East Carolina University Institutional Review Board. 
Primary human muscle cell cultures   
Following a 12-h overnight fast, skeletal muscle from the vastus lateralis of 
subjects was obtained by percutaneous biopsy (Evans, Phinney, & Young, 
1982).  Approximately 40-50 mg of muscle sample was transferred to refrigerated 
low-glucose Dulbecco’s Modified Eagle’s Medium [DMEM; media and media 
supplements were purchased from Gibco (Invitrogen Corporation, Carlsbad, CA) 
unless otherwise stated] and all visible connective and adipose tissue was 
removed prior to culture.  Myoblasts were suspended in growth media (GM) 
[DMEM supplemented with 10% fetal bovine serum (FBS), 0.5 mg/ml BSA, 0.5 
mg/ml fetuin, 20 ng/ml human epidermal growth factor, 0.39 µg/ml 
dexamethasone, and 50 µg/ml gentamicin/amphotericin B (Lonza Inc., 
Walkersville, MD)], and cultured at 37°C in a humidified atmosphere of 5% CO2 
and 95 O2.  After reaching 80-90% confluence, myoblasts from lean and morbidly 
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obese subjects were separately pooled into two banks then subcultured onto T-
75 type I collagen-coated plates (Fisher Scientific, Waltham, MA) followed by 
transfer onto 6-well type I collagen-coated plates (Fisher Scientific).  After 
achieving 80-90% confluence, cells were differentiated by replacing GM with low-
serum differentiation media (DM) [DMEM, 2% heat-inactivated horse serum, 0.5 
mg/ml BSA, 0.5 mg/ml fetuin, and 50 µg/ml gentamicin/amphotericin B].  Media 
was changed every 1-2 days.  Media-containing lipid was prepared by dissolving 
palmitate in ethanol and diluted in DMEM containing 1% BSA and 1 mM 
carnitine.  On the treatment day (day 6), mature myotubes were serum starved 
with fasting media (FM) (DMEM, 0.2% BSA) for 4 h prior to actual treatment.   
The initial experiment involved mytotubes from the lean cell bank exposed 
to 1-h incubations with 0.45 mM palmitate in the presence or absence of 2 mM 
AICAR (Calbiochem, San Diego).  The secondary experiment involved myotubes 
from lean and obese cell banks exposed to a 16-h incubation in one of two 
conditions using DMEM with 1% BSA and 1) no supplementation or 2) 
supplemented with 0.45 mM palmitate.  The final experiment similarly employed 
myotubes from both lean and obese cell banks.  Following serum starvation, cells 
were incubated in one of four 16-h treatments using DMEM with 1% BSA and 1) 
no supplementation (control), 2) supplemented with 0.45 mM palmitate, 3) 
supplemented with 0.45 mM palmitate and 2 mM AICAR, and 4) supplemented 
with 0.45 mM palmitate with 2 mM AICAR added for the final 4 h.  During the final 
10 min of treatment cells were incubated in the presence or absence of 100 nM 
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insulin and subsequently rinsed with DPBS and harvested in 400 µl of ice-cold 
lysis buffer ([50 mM HEPES, 50 mM Na+ pyrophosphate, 100 mM Na+ fluoride, 
50 mM Na+ pyrophosphate, 10 mM Na+ orthovanadate, 10 mM EDTA, 1% Triton 
X-100, and protease and phosphatase (1 and 2) inhibitor cocktails (Sigma, St. 
Louis, MO)] per well and sonicated for 5 sec, followed by a 2-h rotation at 4°C.  
Cell viability was determined by comparison with control before and after 
treatment by trypan blue cell exclusion.   
Immunoblotting  
Total protein content was measured using a BCA protein assay (Pierce, 
Rockford, IL) and individual homogenate volumes were aliquoted into 20 µg and 
200 µg of protein before being frozen in liquid nitrogen and stored at -80°C until 
used for immunoblotting.  For IRS-1, IRS1-pSer312 and IRS1-phosphotyrosine, 
200 µg homogenates were subjected to 10 µl IRS-1 monoclonal IP antibody 
(Santa Cruz Biotech, Santa Cruz, CA) overnight then coupled to protein A 
sepharose beads (Amersham Biosciences, Uppsala Sweden)(for IRS-1 and 
pSer312) or to 40 µl anti-phosphotyrosine-agarose antibody (Sigma-Aldrich, Inc., 
St. Louis, MO), respectively, then rotated for 2 hours at 4°C and eluted with a 
1:10 solution of Bond Breaker TCEP (Pierce, Rockford, IL) and Laemmli Sample 
Buffer (Biorad, Hercules, CA).  Samples were separated by SDS-PAGE using 
7.5% or 10% Tris·HCl gels and then transferred to PVDF membranes for probing 
by appropriate antibodies.  Following incubation with primary antibodies, blots 
were incubated with appropriate HRP-conjugated secondary antibodies.  IRS-1 
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and Phospho-IRS1 Ser307 antibodies were purchased from Millipore (Billerica, 
MA).  Antibodies for phospho-AMPKα (Thr172), AMPKα, phospho-ACC, ACC, 
phospho-Akt-Substrate, and pan-AS160 were purchased from Cell Signaling 
Technologies (Beverly, MA) and phospho-Akt, Akt, IκBα, and actin from Santa 
Cruz Biotech (Santa Cruz, CA).  Horseradish peroxidase activity was assessed 
with ECL solution (Thermo Scientific, Rockford, IL), and exposed to film.  The 
image was scanned and band densitometry was assessed with Gel Pro Analyzer 
software (Media Cybernetics, Silver Spring, MD).  Equal loading of proteins was 
ensured by probing for actin.  Content of phospho-proteins (using phospho-
specific antibodies) was calculated from the density of the band of the phospho-
protein divided by the density of the total protein using the appropriate antibody.   
Statistics   
Data are expressed as means ± SEM of four separate experiments.  
Statistical analyses were performed by one-way ANOVA followed by Tukey’s 
post-hoc test where necessary.  Significance was set at P < 0.05.     
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Results 
1-h Treatment in Lean Myotubes   
In control media, insulin stimulation was associated with reduced pAMPK 
levels (p<0.05; Figure 4.1A), a finding confirmed in other studies (Fediuc et al., 
2008).  Additionally, one hour of lipid incubation had no significant effect on 
pAMPK levels or its substrate, pACC (Figure 4.1B).  In contrast, when AICAR 
was included in the incubation, phosphorylation of both AMPK and ACC 
increased dramatically (p<0.001).  As expected, insulin stimulation significantly 
elevated Akt and AS160 phosphorylation and, whereas levels of pAMPK were 
seemingly unaffected by lipid incubation alone, insulin-stimulated 
phosphorylation of Akt and AS160 was significantly diminished with lipid 
incubation (p<0.001; Figure 4.1C and D).  However, AICAIR co-incubation 
prevented the lipid-induced decrement in Akt and AS160 activation.  Inasmuch 
as IKKβ has been implicated in reducing insulin signaling through its inhibitory 
actions on IRS-1, IκBα, a downstream substrate and inverse indicator of IKKβ, 
was determined as a measure of IKKβ action.  Lipid treatment significantly 
reduced IκBα mass (p<0.05), though this effect was prevented with AICAR co-
incubation (Figure 4.1E).  Moreover, while there was a tendency for insulin 
stimulation to reduce IkBα in control media, this disparity increased with lipid 
treatment (p<0.05).  Finally, insulin stimulation had no significant effect on IRS1-
Ser312 phosphorylation in lean myotubes in control media, although palmitate 
incubation was associated with elevated levels of insulin-stimulated IRS1-pSer312 
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(p<0.05; Figure 4.1F).  Conversely, AICAR inclusion significantly reduced Ser312 
phosphorylation in both basal and insulin-stimulated cells in comparison to both 
control and lipid incubation alone (p<0.01).      
16-h Lipid Treatment in Lean and Obese Myotubes   
We were further interested in comparing myotubes from lean and obese 
subjects and determining whether they exhibit a divergent response to palmitate 
incubation.  Firstly, no baseline differences in pAMPK or pACC were observed 
between lean and obese cells (Figure 4.2A and B).  However, lipid incubation 
appeared to increase the disparity between basal and insulin-stimulated pAMPK 
levels as evident in a significant decrease in pAMPK levels with insulin 
stimulation in lipid treated lean cells (p<0.05).  As a marker of the proximal insulin 
signal, IRS-1 Tyrosine phosphorylation was determined.  Insulin increased IRS1-
pTyr levels in lean cells (p<0.01), but not obese in control media, and insulin-
stimulated IRS1-pTyr levels were greater in lean myotubes compared with obese 
(p<0.01; Figure 4.2C).  However, lipid treatment significantly reduced the ability 
of insulin to stimulate IRS-1 Tyrosine phosphorylation in the lean myotubes.     
In exploring downstream markers of insulin signaling, phosphorylation 
states of both Akt and Akt Substrate of 160 kDa (AS160) were determined.  
Insulin-stimulated pAkt was significantly elevated in all treatments in both lean 
and obese myotubes (Figure 4.2D).  Interestingly, this effect was diminished with 
lipid incubation in lean myotubes only.  In fact, the difference in insulin-stimulated 
pAkt levels between the lean and obese myotubes in control media (p<0.05) 
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were removed upon inclusion of palmitate such that there was no significant 
difference between the two with lipid.  Further, pAS160 levels in the lean 
myotubes followed a similar pattern to pAkt in that insulin resulted in pAS160 
increasing significantly (p<0.01) as well as the effect of palmitate in reducing the 
magnitude of change (Figure 4.2E).  In contrast, insulin stimulation had no effect 
on pAS160 levels in myotubes from obese subjects despite differences in pAkt, 
suggesting an interruption between Akt and AS160 in the obese.    
Baseline differences in IκBα mass were observed between myotubes from 
lean and obese subjects (p<0.01; Figure 4.2F).  Additionally, lipid treatment was 
associated with reduced basal IκBα levels in lean myotubes and the disparity 
between basal and insulin-stimulated levels increased with lipid incubation 
(p<0.05).  Further, IRS1-Ser312 phosphorylation differed drastically between lean 
and obese myotubes in control media (p<0.001; Figure 4.2G).  In contrast to the 
increase in IRS1-pSer312 with lipid incubation in lean myotubes (p<0.05), no 
change was observed in the obese.   
16-h Lipid and AICAR Treatment in Lean and Obese Myotubes   
Upon differences between lean and obese myotubes being observed with 
regards to lipid exposure, a follow-up experiment was performed to determine 
whether AICAR-induced AMPK activation prevents the decrease in insulin 
signaling with lipid exposure and whether lean and obese myotubes respond 
different to AICAR.  When AICAR was included in the palmitate incubation for 
either the final 4 h or the full 16 h treatment period, a robust increase in pAMPK 
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and pACC levels were observed compared to lipid treatment alone in both lean 
and obese myotubes (p<0.001; Figures 4.3A and B).  IRS1-pTyr levels followed a 
similar trend to pAMPK in that AICAR significantly elevated IRS1-pTyr in both 
lean (p<0.001) and obese (p<0.05) myotubes compared with lipid alone (Figure 
4.3C).  Moreover, AICAR inclusion at both time points was associated with 
restoring differences between basal and insulin-stimulated pTyr levels in the lean 
myotubes (p<0.05).  However, despite an increase (p<0.05), AICAR stimulation 
in the obese myotubes did not elevate IRS1-pTyr to similar levels to that seen in 
the lean.   
In looking downstream, insulin-stimulated pAkt increased with AICAR 
inclusion at both time points in the lean and obese myotubes (p<0.01; Figure 
4.3D).  In contrast, pAS160 levels only tended to increase with the 4-h AICAR 
incubation in lean myotubes (p=0.071; Figure 4.3E) while this same 4-h 
treatment significantly elevated basal pAS160 in obese myotubes when 
compared with lipid alone (p<0.05).  Nevertheless, full co-incubation with both 
lipid and AICAR significantly increased both basal and insulin-stimulated pAS160 
levels in lean and obese versus lipid alone (p<0.01), though insulin-stimulated 
pAS160 levels in obese myotubes were lower compared with lean in the same 
treatment (p<0.05).   
IκBα levels were similar between lean and obese myotubes when 
incubated with lipid alone and insulin caused a decrease in IκBα mass in lean 
myotubes (p<0.05; Figure 4.3F).  At both 4 and 16 h of AICAR incubation with 
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lipid, IκBα increased in lean (p<0.01) and obese (p<0.05), though the effect was 
not as robust in the obese myotubes and a difference was observed compared 
with lean (p<0.05).  Additionally, AICAR treatment significantly reduced the 
increase in IRS1-Ser312 phosphorylation induced by lipid incubation in insulin-
stimulated cells in the lean (p<0.05; Figure 4.3G).  Similarly, AICAR inclusion 
significantly reduced IRS1-pSer312 levels in obese myotubes (p<0.01), and IRS1-
Ser312 phosphorylation was significantly elevated in the obese compared with the 
lean in all treatments.     
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Figure 4.1A.  The effects of 1 h of 0.45 mM palmitate with and without AICAR 
inclusion on pooled lean (BMI < 25 m/kg2) myotubes on pAMPK.  Myotubes were 
incubated in control media, 0.45 mM palmitate complexed to 1% BSA in low-
glucose DMEM with 1 mM carnitine, or lipid + AICAR, for 1 h, in the presence 
(black bars) or absence (white bars) of 10 min insulin (100 nM) and probed for 
pAMPK.  All proteins were compared with either the total of its respective 
unphosphorylated protein or actin (not shown).  *p<0.05 for basal vs. insulin 
stimulation within a given treatment.  #p<0.05 for lipid or co-incubation (lipid + 
AICAR) vs. control.  ♦p<0.05 for co-incubation vs. lipid alone.   
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Figure 4.1B.  The effects of 1 h of 0.45 mM palmitate with and without AICAR 
inclusion on pooled lean (BMI < 25 m/kg2) myotubes on pACC.  Myotubes were 
incubated in control media, 0.45 mM palmitate complexed to 1% BSA in low-
glucose DMEM with 1 mM carnitine, or lipid + AICAR, for 1 h, in the presence 
(black bars) or absence (white bars) of 10 min insulin (100 nM) and probed for 
pACC.  All proteins were compared with either the total of its respective 
unphosphorylated protein or actin (not shown).  *p<0.05 for basal vs. insulin 
stimulation within a given treatment.  #p<0.05 for lipid or co-incubation (lipid + 
AICAR) vs. control.  ♦p<0.05 for co-incubation vs. lipid alone.   
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Figure 4.1C.  The effects of 1 h of 0.45 mM palmitate with and without AICAR 
inclusion on pooled lean (BMI < 25 m/kg2) myotubes on pAkt.  Myotubes were 
incubated in control media, 0.45 mM palmitate complexed to 1% BSA in low-
glucose DMEM with 1 mM carnitine, or lipid + AICAR, for 1 h, in the presence 
(black bars) or absence (white bars) of 10 min insulin (100 nM) and probed for 
pAkt.  All proteins were compared with either the total of its respective 
unphosphorylated protein or actin (not shown).  *p<0.05 for basal vs. insulin 
stimulation within a given treatment.  #p<0.05 for lipid or co-incubation (lipid + 
AICAR) vs. control.  ♦p<0.05 for co-incubation vs. lipid alone.   
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Figure 4.1D.  The effects of 1 h of 0.45 mM palmitate with and without AICAR 
inclusion on pooled lean (BMI < 25 m/kg2) myotubes on pAS160.  Myotubes were 
incubated in control media, 0.45 mM palmitate complexed to 1% BSA in low-
glucose DMEM with 1 mM carnitine, or lipid + AICAR, for 1 h, in the presence 
(black bars) or absence (white bars) of 10 min insulin (100 nM) and probed for 
pAS160.  All proteins were compared with either the total of its respective 
unphosphorylated protein or actin (not shown).  *p<0.05 for basal vs. insulin 
stimulation within a given treatment.  #p<0.05 for lipid or co-incubation (lipid + 
AICAR) vs. control.  ♦p<0.05 for co-incubation vs. lipid alone.   
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Figure 4.1E.  The effects of 1 h of 0.45 mM palmitate with and without AICAR 
inclusion on pooled lean (BMI < 25 m/kg2) myotubes on IκBα.  Myotubes were 
incubated in control media, 0.45 mM palmitate complexed to 1% BSA in low-
glucose DMEM with 1 mM carnitine, or lipid + AICAR, for 1 h, in the presence 
(black bars) or absence (white bars) of 10 min insulin (100 nM) and probed for 
IκBα.  All proteins were compared with either the total of its respective 
unphosphorylated protein or actin (not shown).  *p<0.05 for basal vs. insulin 
stimulation within a given treatment.  #p<0.05 for lipid or co-incubation (lipid + 
AICAR) vs. control.  ♦p<0.05 for co-incubation vs. lipid alone.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
103
0.0
0.5
1.0
1.5
2.0
Insulin
Lipid
AICAR
-
-
- - -
- -
+ +
++
+
++
++
-
-
#
#
p
S
e
r3
1
2
:T
o
ta
l 
IR
S
-1
 (
A
U
)
 
Figure 4.1F.  The effects of 1 h of 0.45 mM palmitate with and without AICAR 
inclusion on pooled lean (BMI < 25 m/kg2) myotubes on pSer312.  Myotubes were 
incubated in control media, 0.45 mM palmitate complexed to 1% BSA in low-
glucose DMEM with 1 mM carnitine, or lipid + AICAR, for 1 h, in the presence 
(black bars) or absence (white bars) of 10 min insulin (100 nM) and probed for 
IRS1-pSer312.  All proteins were compared with either the total of its respective 
unphosphorylated protein or actin (not shown).  *p<0.05 for basal vs. insulin 
stimulation within a given treatment.  #p<0.05 for lipid or co-incubation (lipid + 
AICAR) vs. control.  ♦p<0.05 for co-incubation vs. lipid alone.   
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Figure 4.2A.  The effects of 16 h of 0.45 mM palmitate exposure on pooled 
myotubes from lean (BMI < 25 m/kg2) and morbidly obese (BMI > 40 m/kg2) 
humans on pAMPK.  Myotubes were incubated in control media (white bars) or 
0.45 mM palmitate complexed to 1% BSA in low-glucose DMEM with 1 mM 
carnitine (black bars), in the presence or absence of 10 min insulin (100 nM) and 
probed for pAMPK.  All proteins were compared with either the total of its 
respective unphosphorylated protein or actin (not shown).   *p<0.05 for basal vs. 
insulin stimulation within a given treatment.  #p<0.05 for lipid vs. control.  
♦p<0.05 for obese vs. lean within a given treatment.   
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Figure 4.2B.  The effects of 16 h of 0.45 mM palmitate exposure on pooled 
myotubes from lean (BMI < 25 m/kg2) and morbidly obese (BMI > 40 m/kg2) 
humans on pACC.  Myotubes were incubated in control media (white bars) or 
0.45 mM palmitate complexed to 1% BSA in low-glucose DMEM with 1 mM 
carnitine (black bars), in the presence or absence of 10 min insulin (100 nM) and 
probed for pACC.  All proteins were compared with either the total of its 
respective unphosphorylated protein or actin (not shown).   *p<0.05 for basal vs. 
insulin stimulation within a given treatment.  #p<0.05 for lipid vs. control.  
♦p<0.05 for obese vs. lean within a given treatment.   
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Figure 4.2C.  The effects of 16 h of 0.45 mM palmitate exposure on pooled 
myotubes from lean (BMI < 25 m/kg2) and morbidly obese (BMI > 40 m/kg2) 
humans on IRS1-pTyr.  Myotubes were incubated in control media (white bars) 
or 0.45 mM palmitate complexed to 1% BSA in low-glucose DMEM with 1 mM 
carnitine (black bars), in the presence or absence of 10 min insulin (100 nM) and 
probed for IRS1-pTyr.  All proteins were compared with either the total of its 
respective unphosphorylated protein or actin (not shown).   *p<0.05 for basal vs. 
insulin stimulation within a given treatment.  #p<0.05 for lipid vs. control.  
♦p<0.05 for obese vs. lean within a given treatment.   
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Figure 4.2D.  The effects of 16 h of 0.45 mM palmitate exposure on pooled 
myotubes from lean (BMI < 25 m/kg2) and morbidly obese (BMI > 40 m/kg2) 
humans pAkt.  Myotubes were incubated in control media (white bars) or 0.45 
mM palmitate complexed to 1% BSA in low-glucose DMEM with 1 mM carnitine 
(black bars), in the presence or absence of 10 min insulin (100 nM) and probed 
for pAkt.  All proteins were compared with either the total of its respective 
unphosphorylated protein or actin (not shown).   *p<0.05 for basal vs. insulin 
stimulation within a given treatment.  #p<0.05 for lipid vs. control.  ♦p<0.05 for 
obese vs. lean within a given treatment.   
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Figure 4.2E.  The effects of 16 h of 0.45 mM palmitate exposure on pooled 
myotubes from lean (BMI < 25 m/kg2) and morbidly obese (BMI > 40 m/kg2) 
humans pAS160.  Myotubes were incubated in control media (white bars) or 0.45 
mM palmitate complexed to 1% BSA in low-glucose DMEM with 1 mM carnitine 
(black bars), in the presence or absence of 10 min insulin (100 nM) and probed 
for pAS160.  All proteins were compared with either the total of its respective 
unphosphorylated protein or actin (not shown).   *p<0.05 for basal vs. insulin 
stimulation within a given treatment.  #p<0.05 for lipid vs. control.  ♦p<0.05 for 
obese vs. lean within a given treatment.   
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Figure 4.2F.  The effects of 16 h of 0.45 mM palmitate exposure on pooled 
myotubes from lean (BMI < 25 m/kg2) and morbidly obese (BMI > 40 m/kg2) 
humans on IκBα.  Myotubes were incubated in control media (white bars) or 0.45 
mM palmitate complexed to 1% BSA in low-glucose DMEM with 1 mM carnitine 
(black bars), in the presence or absence of 10 min insulin (100 nM) and probed 
for pIκBα.  All proteins were compared with either the total of its respective 
unphosphorylated protein or actin (not shown).   *p<0.05 for basal vs. insulin 
stimulation within a given treatment.  #p<0.05 for lipid vs. control.  ♦p<0.05 for 
obese vs. lean within a given treatment.   
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Figure 4.2G.  The effects of 16 h of 0.45 mM palmitate exposure on pooled 
myotubes from lean (BMI < 25 m/kg2) and morbidly obese (BMI > 40 m/kg2) 
humans on pSer312.  Myotubes were incubated in control media (white bars) or 
0.45 mM palmitate complexed to 1% BSA in low-glucose DMEM with 1 mM 
carnitine (black bars), in the presence or absence of 10 min insulin (100 nM) and 
probed for IRS-1 pSer312.  All proteins were compared with either the total of its 
respective unphosphorylated protein or actin (not shown).   *p<0.05 for basal vs. 
insulin stimulation within a given treatment.  #p<0.05 for lipid vs. control.  
♦p<0.05 for obese vs. lean within a given treatment.   
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Figure 4.3A.  The effects of 16 h of 0.45 mM palmitate and AICAR exposure on 
pooled myotubes from lean (BMI < 25 m/kg2) and morbidly obese (BMI > 40 
m/kg2) humans on pAMPK.  Myotubes were incubated in 0.45 mM palmitate 
complexed to 1% BSA in low-glucose DMEM with 1 mM carnitine (white bars), 
lipid + 4-h AICAR (grey bars), or lipid + 16-h AICAR, in the presence or absence 
of 10 min insulin (100 nM) and probed for pAMPK.  All proteins were compared 
with either the total of its respective unphosphorylated protein or actin (not 
shown).  *p<0.05 for basal vs. insulin stimulation within a given treatment.  
#p<0.05 for co-incubations (4 and 16 h) vs. lipid alone within a give group.  
♦p<0.05 for obese vs. lean within a given treatment. 
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 Figure 4.3B.  The effects of 16 h of 0.45 mM palmitate and AICAR exposure on 
pooled myotubes from lean (BMI < 25 m/kg2) and morbidly obese (BMI > 40 
m/kg2) humans on pACC.  Myotubes were incubated in 0.45 mM palmitate 
complexed to 1% BSA in low-glucose DMEM with 1 mM carnitine (white bars), 
lipid + 4-h AICAR (grey bars), or lipid + 16-h AICAR, in the presence or absence 
of 10 min insulin (100 nM) and probed for pACC.  All proteins were compared 
with either the total of its respective unphosphorylated protein or actin (not 
shown).  *p<0.05 for basal vs. insulin stimulation within a given treatment.  
#p<0.05 for co-incubations (4 and 16 h) vs. lipid alone within a give group.  
♦p<0.05 for obese vs. lean within a given treatment. 
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Figure 4.3C.  The effects of 16 h of 0.45 mM palmitate and AICAR exposure on 
pooled myotubes from lean (BMI < 25 m/kg2) and morbidly obese (BMI > 40 
m/kg2) humans on IRS1-pTyr.  Myotubes were incubated in 0.45 mM palmitate 
complexed to 1% BSA in low-glucose DMEM with 1 mM carnitine (white bars), 
lipid + 4-h AICAR (grey bars), or lipid + 16-h AICAR, in the presence or absence 
of 10 min insulin (100 nM) and probed for IRS1-pTyr.  All proteins were 
compared with either the total of its respective unphosphorylated protein or actin 
(not shown).  *p<0.05 for basal vs. insulin stimulation within a given treatment.  
#p<0.05 for co-incubations (4 and 16 h) vs. lipid alone within a give group.  
♦p<0.05 for obese vs. lean within a given treatment. 
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 Figure 4.3D.  The effects of 16 h of 0.45 mM palmitate and AICAR exposure on 
pooled myotubes from lean (BMI < 25 m/kg2) and morbidly obese (BMI > 40 
m/kg2) humans on pAkt.  Myotubes were incubated in 0.45 mM palmitate 
complexed to 1% BSA in low-glucose DMEM with 1 mM carnitine (white bars), 
lipid + 4-h AICAR (grey bars), or lipid + 16-h AICAR, in the presence or absence 
of 10 min insulin (100 nM) and probed for pAkt.  All proteins were compared with 
either the total of its respective unphosphorylated protein or actin (not shown).  
*p<0.05 for basal vs. insulin stimulation within a given treatment.  #p<0.05 for co-
incubations (4 and 16 h) vs. lipid alone within a give group.  ♦p<0.05 for obese 
vs. lean within a given treatment. 
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 Figure 4.3E.  The effects of 16 h of 0.45 mM palmitate and AICAR exposure on 
pooled myotubes from lean (BMI < 25 m/kg2) and morbidly obese (BMI > 40 
m/kg2) humans on pAS160.  Myotubes were incubated in 0.45 mM palmitate 
complexed to 1% BSA in low-glucose DMEM with 1 mM carnitine (white bars), 
lipid + 4-h AICAR (grey bars), or lipid + 16-h AICAR, in the presence or absence 
of 10 min insulin (100 nM) and probed for pAS160.  All proteins were compared 
with either the total of its respective unphosphorylated protein or actin (not 
shown).  *p<0.05 for basal vs. insulin stimulation within a given treatment.  
#p<0.05 for co-incubations (4 and 16 h) vs. lipid alone within a give group.  
♦p<0.05 for obese vs. lean within a given treatment. 
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 Figure 4.3F.  The effects of 16 h of 0.45 mM palmitate and AICAR exposure on 
pooled myotubes from lean (BMI < 25 m/kg2) and morbidly obese (BMI > 40 
m/kg2) humans on IκBα.  Myotubes were incubated in 0.45 mM palmitate 
complexed to 1% BSA in low-glucose DMEM with 1 mM carnitine (white bars), 
lipid + 4-h AICAR (grey bars), or lipid + 16-h AICAR, in the presence or absence 
of 10 min insulin (100 nM) and probed for IκBα.  All proteins were compared with 
either the total of its respective unphosphorylated protein or actin (not shown).  
*p<0.05 for basal vs. insulin stimulation within a given treatment.  #p<0.05 for co-
incubations (4 and 16 h) vs. lipid alone within a give group.  ♦p<0.05 for obese 
vs. lean within a given treatment. 
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Figure 4.3G.  The effects of 16 h of 0.45 mM palmitate and AICAR exposure on 
pooled myotubes from lean (BMI < 25 m/kg2) and morbidly obese (BMI > 40 
m/kg2) humans on pSer312.  Myotubes were incubated in 0.45 mM palmitate 
complexed to 1% BSA in low-glucose DMEM with 1 mM carnitine (white bars), 
lipid + 4-h AICAR (grey bars), or lipid + 16-h AICAR, in the presence or absence 
of 10 min insulin (100 nM) and probed for IRS1-pSer312.  All proteins were 
compared with either the total of its respective unphosphorylated protein or actin 
(not shown).  *p<0.05 for basal vs. insulin stimulation within a given treatment.  
#p<0.05 for co-incubations (4 and 16 h) vs. lipid alone within a give group.  
♦p<0.05 for obese vs. lean within a given treatment. 
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Discussion 
 The findings from the current study support the mounting evidence that 
saturated fatty acids induce insulin resistance in skeletal muscle via decay of the 
insulin signal.  Specifically, we found that a 1- or 16-h incubation of the saturated 
fatty acid palmitate with myotubes from lean humans elicited a significant 
reduction in IκBα mass and insulin-stimulated phosphorylation of Akt and AS160 
as well as an elevation in IRS-1 Ser312 phosphorylation and that the effects of 
lipid incubation were completely prevented with AICAR inclusion.  In agreement 
with our previous findings (Bell et al., unpublished data), the current evidence 
supports the conclusion that myotubes from morbidly obese individuals are 
resistant to insulin-stimulated signal transduction as well as the detrimental 
effects of lipid exposure on this signal.  This was evident with a 16-h lipid 
treatment, in contrast to the lean, by the absence of a reduction in insulin-
stimulated IRS-1 Tyr phosphorylation, levels of phospho-Akt, and phospho-
AS160.  Further, whereas lipid exposure significantly reduced IκBα levels and 
increased IRS1-pSer312 in lean myotubes, no effect was observed in the obese.  
However, despite a divergent response to lipid between lean and obese 
myotubes, AICAR inclusion restored insulin signaling at every measured step in 
the lean and improved the signal in obese.   
The concentration and type of fatty acid treatment used in this study 
follows the work of many others (Chavez et al., 2003; Coll et al., 2008; Fediuc et 
al., 2008; Jove et al., 2005; Jove et al., 2006; Montell et al., 2001; Pimenta et al., 
  
119
2008; Weigert et al., 2004; Wu, Song, Xu, Zhang, & Zou, 2007).  Palmitate is the 
major saturated fatty acid within the body and circulating levels of free fatty acids 
in obese humans have been found to be as high as 800 µM (Roden, 2004).  
Additionally, saturated fatty acids such as palmitate have been shown to exhibit a 
particularly striking contrast in regards to its ability to activate lipid-sensitive 
kinases and reduce both the proximal (IRS-1) and distal (Akt, AS160) insulin 
signal when compared with unsaturated fats (Coll et al., 2006; Y. Wu et al., 
2007).   
Recent advances in the area of obesity and diabetes research have 
revealed a role for various lipid-stimulated  kinases that act at IRS-1 and result in 
attenuation of the insulin signal, namely IKKβ, PKCθ, and JNK1 (Holland et al., 
2007).  We previously reported differences in IκBα protein levels, an inverse 
measure of IKKβ action, and IRS1-Ser312 phosphorylation in vastus lateralis of 
lean and morbidly obese humans (Bikman et al., 2008) and herein report a 
retention of this disparity in cultured myotubes.  Moreover, in the lipid- and 
insulin-sensitive lean myotubes we observed a significant decrease in IκBα levels 
when exposed to lipid and insulin concurrently in both the 1- and 16-h 
treatments.  Lipid-induced reductions in IκBα levels have been observed as early 
as 30 min after lipid inclusion (Weigert et al., 2004) and our findings of a 
decrease in IκBα after 10 min were somewhat unexpected.  However, a key 
difference in the current study is the presence of insulin.  Insulin’s anabolic role 
encourages the rapid influx and storage of fatty acids in skeletal muscle (Pimenta 
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et al., 2008) and the decrement in IκBα after 10 min of insulin treatment in the 
current study may be a function of the synergistic effects of lipid and insulin 
resulting in a rapid uptake of lipid in the absence of a comparable increase in 
oxidation.   
In support for our findings implicating a role for IKKβ in mediating lipid-
induced insulin resistance in muscle, Sinha et al. (2004) observed that 6 h of 
palmitate exposure in L6 myotubes resulted in a significant decrease in insulin-
stimulated glucose uptake, as well as reduced IκBα mass and phospho-Akt 
levels.  However, when IKKβ action was prevented with inclusion of the IKKβ-
specific inhibitor salicylate, signaling was rescued.  Additionally, IKKβ inhibition 
through salicylate treatment in rodents has been shown to be associated with 
improved glucose tolerance and improved lipid profile (Kim et al., 2001; Yuan et 
al., 2001).  Also, heterozygous IKKβ+/- mice fed a high-fat diet have been found 
to have lower fasting insulin and glucose values compared with IKKβ+/+ 
littermates (Yuan et al., 2001).  Further, Kim et al. (2001) observed that IKKβ 
knock out mice did not display any decrement in skeletal muscle insulin signaling 
with lipid infusion.   
Additionally, an unexpected observation was the effect of AICAR inclusion 
on phosphorylation of Akt.   Specifically, lipid incubation significantly reduced the 
ability of insulin to stimulate Akt phosphorylation in the lean (Figure 2D), 
however, compared to lipid alone, AICAR dramatically increased insulin-
stimulated phospho-Akt in both lean and obese (Figure 3D).  However, AMPK 
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has been shown to induce glucose uptake through activation of AS160, which is 
downstream of Akt (Thong et al., 2007).  Additionally, the observation that in the 
absence of insulin Akt phosphorylation was unchanged with or without AICAR 
suggests, in contrast to AS160 phosphorylation, that AMPK is not acting directly 
on Akt, but is rather facilitating the ability of insulin to stimulate Akt 
phosphorylation.  With this in mind, it is tempting to speculate that AICAR-
stimulated AMPK activation attenuates the lipid-induced decrement in upstream 
insulin signaling (Figure 4).  Regarding the latter option, research in various cell 
types has revealed a role for AMPK in inhibiting NF-κB pathway activity 
(Cacicedo et al., 2004; Giri et al., 2004; Hattori et al., 2006) though evidence of 
this effect in skeletal muscle is scarce and contrasting (Ho et al., 2005; Lihn et 
al., 2008; Steinberg et al., 2006).  Considering that AICAR treatment  in human 
myotubes has also been found to decrease cytokine production (Lihn et al., 
2008), we feel that these observations, in addition to our own findings that 
AICAR-stimulated AMPK activation restores IκBα levels in the lean and elevates 
levels above normal in the morbidly obese, suggest a potential role for AMPK in 
preventing activation of IKKβ in response to lipid.   
As mentioned, in exploring the distal insulin signal we observed an 
unexpected incongruity between Akt and AS160 phosphorylation.  AICAR 
treatment increased insulin-stimulated Akt phosphorylation in both basal and 
insulin-stimulated myotubes at both 4 and 16 h of incubation.  However, AICAR 
treatment elicited an increase in phospho-AS160 even in the absence of insulin, 
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offering support for AMPK’s direct action on AS160 (Thong et al., 2007).  In 
addition, we observed that AICAR-stimulated AMPK activity only increased 
phospho-AS160 with full AICAR + lipid co-incubation and that inclusion of AICAR 
in the final 4 h of treatment elicited a far less dramatic effect.  This difference may 
represent an inability of AICAR-stimulated AMPK activity to fully restore the 
decay of the insulin signal following a prolonged period of lipid incubation alone, 
whereas AICAR inclusion at the onset of lipid incubation can prevent this decay.  
The ability of AMPK action to prevent lipid-induced insulin resistance has been 
recently explored in skeletal muscle.  Fujii et al. (Fujii et al., 2008) found reduced 
insulin receptor-β subunit, IRS-1, and Akt protein levels in muscle-specific 
transgenic (TG) mice expressing an inactive form of AMPKα2 when fed a high-fat 
diet compared with wild type controls fed the same diet.  Further, whereas 
muscle levels of DAG did not differ between the mice on control diet, DAG levels 
were significantly elevated in TG mice versus control when fed a high-fat diet.  
These observations correlated with a reduction in insulin-stimulated glucose 
uptake in isolated soleus of TG mice.   
In summary, the present study shows a divergent response to palmitate 
incubation between myotubes from lean and morbidly humans.  Palmitate 
incubation in lean myotubes was associated with reduced IκBα protein mass, 
reduced phosphorylation of IRS1-Tyr, Akt, and AS160, and elevated IRS-1 Ser312 
phosphorylation, while the myotubes from the morbidly obese did not appear to 
be significantly affected.  In AICAR + lipid co-incubation, AICAR-stimulated 
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AMPK activity prevented the decay in insulin signaling observed with lipid alone, 
though AICAR inclusion in the final 4 h of lipid incubation was not sufficient to 
restore AS160 phosphorylation.   Additionally, AMPK activation was associated 
with reduced IKKβ action.  We conclude that AMPK activation prevents lipid-
induced insulin resistance in both lean and obese myotubes possibly through the 
inhibition of lipid-stimulated serine kinases.  These findings suggest an important 
role for regular exercise in addition to offering a potential mechanism of action for 
oral AMPK-activating agents, such as TZDs and metformin.   
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 Exploration into the etiology of type 2 diabetes mellitus has discovered the 
vital role of the insulin receptor substrate proteins (IRS) in insulin-sensitive tissue 
like skeletal muscle.  In particular, IRS-1 has received a great deal of attention 
due to the various factors that play a role in impeding its function, primarily lipid-
sensitive kinases like the inhibitor of κB kinase β (IKKβ).  In contrast, mounting 
evidence supports the role of AMPK as a vital component in known insulin-
sensitizing agents, although the mechanism through which AMPK facilitates the 
insulin signal is unknown (Figure 1.1).  In addition to further exploring the various 
molecules that have been found to mediate IRS-1 function, we feel that 
elucidating the role of AMPK in preventing the development of insulin resistance 
and treating overt diabetes may be very beneficial.   
 The purpose of this project was to i) determine whether baseline 
differences in AMP-activated protein kinase (AMPK) activity account for the 
disparity in insulin sensitivity between post-bypass patients and control subjects; 
ii) determine the effect of chronic metformin administration (an AMPK activator) 
on whole-body insulin sensitivity and skeletal muscle insulin signaling in lean and 
obese Zucker rats; and iii) explore the ability of AICAR-stimulated AMPK activity 
to prevent and/or reverse the deleterious consequences of palmitate exposure on 
insulin signaling in myotubes from lean and morbidly obese humans.   
 Collectively, these studies serve to i) confirm previous findings regarding 
the presence of insulin signaling defects in skeletal muscle, particularly the role 
of IKKβ and IRS1-pSer312/307; ii) reveal a potential mechanism for the dramatic 
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improvement in insulin sensitivity following surgery-induced weight loss; iii) 
establish the differential effects of metformin in stimulating AMPK activity and 
improving insulin signaling in muscle fiber types and obesity state; iv) confirm 
previous findings of the retention in cultured myotubes of insulin signaling defects 
evident in vivo; and v) offer a novel finding of the ability of AICAR-stimulated 
AMPK activation to prevent lipid-induced insulin resistance via preservation of 
the insulin signal.   
Firstly, we measured IRS1-pSer312 and IκBα protein levels, as a surrogate 
for IKKβ activity, as well as AMPK phosphorylation in the vastus lateralis of post-
bypass patients and control subjects and found that IκBα mass and IRS1-
phospho-Ser312 protein levels in skeletal muscle from post-surgery patients were 
similar to that seen in muscle from lean subjects despite the post-surgery group 
having a significantly higher BMI.  Additionally, we observed a significant 
elevation in AMPK phosphorylation in the muscle of post-bypass patients 
compared with all other groups.  While this observation did not support our 
hypothesis that baseline differences in insulin signaling may be accounted for by 
various rates of AMPK activity, we feel it may nonetheless assist in explaining the 
improvements in insulin signaling in the post-bypass group.  The disparity in 
phospho-AMPK seen in the post-bypass group compared with the control 
subjects may be a function of the varying role of AMPK-stimulating hormones 
that accompany the surgery and the subsequent tremendous weight loss.  In 
particular, adiponectin is a hormone released from the adipocytes that has been 
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shown to stimulate AMPK activity in skeletal muscle (Hardie, 2004) and 
circulating levels of adiponectin have been shown to be elevated following gastric 
bypass (de Carvalho et al., 2008; de la Torre et al., 2008).  Moreover, lifestyle 
intervention in individuals suffering from type 2 diabetes also elicits a significant 
improvement in adiponectin levels (Kadoglou et al., 2007).  Alternatively, the 
elevations in phospho-AMPK observed in the post-bypass group may be a 
function of reduced stomach volume and a heightened sensitivity to fasting in the 
post-bypass group.  AMPK has been shown to mediate a host of adaptations in 
skeletal muscle in response to fasting to promote fatty acid oxidation, including 
elevated expression of CD36 and CPT1, which would encourage fatty acid flux 
into the cell and shuttling into the mitochondria (Long et al., 2005; Long & 
Zierath, 2008).  Muscle biopsies were pulled from subjects following an overnight 
fast and due to the drastically reduced stomach volume of the post-bypass 
patients, it is highly possible that these subjects eat relatively less during the final 
meal on the night preceding the biopsy and are subsequently in a greater state of 
nutrient deprivation the following day.  This heighted sensitivity to fasting (being 
in a more severe state of nutrient deprivation) may be sensed in the skeletal 
muscle of post-bypass patients and AMPK is activated in response.    
Secondly, we investigated the correlation between AMPK and IKKβ 
activity in the muscle of lean and obese Zucker rats and, similar to our previous 
findings, observed no correlation between baseline differences insulin sensitivity 
and signaling and AMPK phosphorylation.  However, in exploring the beneficial 
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effects of metformin treatment on metabolic function, we found not only an 
elevation in AMPK action, but also IκBα levels in WG of obese, insulin-resistant 
rodents.  This finding is an indication of reduced IKKβ activity and suggests that 
metformin treatment is able to stimulate AMPK and reduce IKKβ activity within 
the muscle.  Moreover, these observations were associated with improved insulin 
signaling, as evidenced by reduced IRS1-pSer307 levels.  Finally, levels of IκBα 
and IRS1-Ser307 were significantly and inversely correlated with metformin-
treated obese rats, but only in white muscle, suggesting a fiber-type specific 
action of metformin on the IKKβ signaling pathway.  The fiber-type specific effect 
of metformin may be a function of two possibilities.  First, the white muscle in the 
obese rats may contain higher-than-normal levels of lipid due to the gross obesity 
associated with the fat Zucker rat, and, not being able to handle such high levels 
of lipid, unlike red muscle, lipid metabolite levels may be higher and, hence, lipid-
sensitive kinases may be in a greater state of activation.  In fact, muscle levels of 
the lipid metabolite diacylglycerol (DAG) and PKC activity have been found to be 
higher in obese Zucker rats compared with lean controls (Qu, Seale, & Donnelly, 
1999).  Alternatively, given metformin’s actions on mitochondrial function, due to 
the relatively reduced abundance of mitochondria within white muscle compared 
to red muscle, it is possible that the given dose and time period of treatment of 
metformin was sufficient to elicit an observable effect in white muscle, though 
insufficient to evoke the same response in the mitochondria-rich red muscle.   
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Lastly, we found that a 1-h incubation of the saturated fatty acid palmitate 
with myotubes from lean humans elicited a significant reduction in insulin-
stimulated phospho-Akt and IκBα mass as well as an elevation in IRS-1 Ser312 
phosphorylation and that the effects of lipid incubation were completely 
prevented with AICAR inclusion.  Moreover, we offered evidence that myotubes 
from obese individuals appear to be largely resistant to the detrimental effects of 
lipid exposure.  This was evident, in contrast to the lean, by the absence of a 
reduction in insulin-stimulated IRS-1 tyrosine phosphorylation with a 16-h lipid 
treatment, as well as no decrement in levels of phospho-Akt and phospho-
AS160.  Further, whereas lipid exposure significantly reduced IκBα levels and 
increased IRS1-pSer312 in lean myotubes, no effect was observed in the obese.  
However, despite a divergent response to lipid between lean and obese 
myotubes, AICAR inclusion restored insulin signaling at every measured step in 
the lean and improved the signal in obese.  From this it appears that AMPK 
activation prevents lipid-induced insulin resistance in both lean and obese 
myotubes possibly through the inhibition of lipid-stimulated serine kinases.  
These findings suggest an important role for regular exercise in addition to 
offering a potential mechanism of action for oral AMPK-activating agents, such 
as TZDs and metformin. 
The findings of this project support the mounting evidence in favor of the 
inhibitory effect of intracellular lipid species on insulin signal transduction.  In 
particular, lipid-sensitive kinases, such as IKKβ, have been shown to reduce 
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insulin signaling and exacerbate skeletal muscle insulin resistance by serine 
phosphorylation of IRS-1.  Due to its location at the proximal end of the pathway, 
any dysfunction in the action of IRS-1 can result in disruption of the entire 
cascade.  Yamauchi et al. (Yamauchi et al., 1996) observed that skeletal muscle 
from IRS1-deficient rodents exhibited reduced insulin-stimulated glucose uptake.  
Further, it has been shown using short interfering (si) RNA-mediated ablation of 
IRS-1 that the loss of IRS-1 function results in reduced insulin-stimulated glucose 
uptake, Akt phosphorylation, and GLUT4 translocation (Huang et al., 2005). 
An ever-increasing amount of research offers support for the role of 
inflammatory cytokines and NF-κB pathway intermediates, such as IKKβ, to 
inhibit insulin signaling.  Interestingly, research into the role of AMPK has 
revealed its presence and function in more and more cellular processes, from 
glucose uptake to gene expression.  Whereas the immune and metabolic 
systems were once thought of as distinct, they appear to work jointly in 
maintaining healthy function.  These systems represent the most indispensable 
abilities within an organism—the ability to defend itself against infection and heal 
and the ability to store energy for times of low nutrient availability and high 
energy demand (Wellen & Hotamisligil, 2005).  As such, these systems are 
interdependent and work synergistically to maintain homeostasis.  Moreover, it is 
tempting to seek a relationship between two of the more prominent players in 
their respective systems, namely IKKβ in the immune system and AMPK in the 
metabolic system.  Hence, we feel it is valuable and potentially beneficial to 
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determine the effect of AMPK manipulation in skeletal muscle in attenuating lipid-
induced insulin resistance via inhibition of IKKβ. 
In summary, we have demonstrated that IRS-1 Ser312 phosphorylation and 
IKKβ action differ in the skeletal muscle of lean and obese individuals and that 
this disparity is resolved following surgery-induced weight loss and accompanied 
by an increase in AMPK phosphorylation.  Moreover, through the use of AMPK-
activating agents both in vivo and in cell culture, we have attempted to establish 
AMPK’s ability, albeit indirectly, to mediate proximal insulin signaling events 
possibly through the inhibition of lipid-sensitive kinases.  These findings present 
a valuable contribution to the understanding and treatment of insulin resistance 
associated with type 2 diabetes mellitus and human obesity.   
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